Original Article

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

Kevan C. Herold, M.D., William Hagopian, M.D., Ph.D., Julie A. Auger, B.A., Ena Poumian-Ruiz, B.S., Lesley Taylor, B.A., David Donaldson, M.D., Stephen E. Gitelman, M.D., David M. Harlan, M.D., Danlin Xu, Ph.D., Robert A. Zivin, Ph.D., and Jeffrey A. Bluestone, Ph.D.

N Engl J Med 2002; 346:1692-1698May 30, 2002DOI: 10.1056/NEJMoa012864

Abstract

Background

Type 1 diabetes mellitus is a chronic autoimmune disease caused by the pathogenic action of T lymphocytes on insulin-producing beta cells. Previous clinical studies have shown that continuous immune suppression temporarily slows the loss of insulin production. Preclinical studies suggested that a monoclonal antibody against CD3 could reverse hyperglycemia at presentation and induce tolerance to recurrent disease.

Full Text of Background...

Methods

We studied the effects of a nonactivating humanized monoclonal antibody against CD3 — hOKT3γ1(Ala-Ala) — on the loss of insulin production in patients with type 1 diabetes mellitus. Within 6 weeks after diagnosis, 24 patients were randomly assigned to receive either a single 14-day course of treatment with the monoclonal antibody or no antibody and were studied during the first year of disease.

Full Text of Methods...

Results

Treatment with the monoclonal antibody maintained or improved insulin production after one year in 9 of the 12 patients in the treatment group, whereas only 2 of the 12 controls had a sustained response (P=0.01). The treatment effect on insulin responses lasted for at least 12 months after diagnosis. Glycosylated hemoglobin levels and insulin doses were also reduced in the monoclonal-antibody group. No severe side effects occurred, and the most common side effects were fever, rash, and anemia. Clinical responses were associated with a change in the ratio of CD4+ T cells to CD8+ T cells 30 and 90 days after treatment.

Full Text of Results...

Conclusions

Treatment with hOKT3γ1(Ala-Ala) mitigates the deterioration in insulin production and improves metabolic control during the first year of type 1 diabetes mellitus in the majority of patients. The mechanism of action of the anti-CD3 monoclonal antibody may involve direct effects on pathogenic T cells, the induction of populations of regulatory cells, or both.

Full Text of Discussion...

Read the Full Article...

Media in This Article

Figure 1Changes from Study Entry to 12 Months in the Total C-Peptide Response to Mixed-Meal Tolerance Testing.

Figure 2Mean CD4+ and CD8+ T-Cell Counts in the Monoclonal-Antibody Group According to the Presence or Absence of a Response to Treatment.

Article Activity

394 articles have cited this article

Article

Type 1 diabetes mellitus is a T-cell–mediated autoimmune disease that begins, in many cases, three to five years before the onset of clinical symptoms, continues after diagnosis, and can recur after islet transplantation.1-3 The effector mechanisms responsible for the destruction of beta cells involve cytotoxic T cells as well as soluble T-cell products, such as interferon-γ, tumor necrosis factor α, and others.4 Such observations have led to clinical trials with immunomodulatory drugs such as cyclosporine, azathioprine, prednisone, and antithymocyte globulin, which were shown to cause transient improvement in clinical measures and to enhance the rate of non–insulin-requiring remissions when initiated soon after diagnosis.5-8 Unfortunately, the toxic effects of such drugs, concern about the risk associated with immune suppression, and the need for continuous treatment in an otherwise healthy, young population limit the use of these agents.9

We,10 as well as Chatenoud et al.,11-13 have reported that treatment of mice with a modified monoclonal antibody against CD3 that had been altered to prevent binding to the Fc receptor prevents or reverses diabetes in nonobese diabetic mice and other mouse models of type 1 diabetes mellitus. This antibody can be used without toxic effects such as the high fevers and hypotension that are typically associated with T-cell activation in vivo.10-13 Initial studies in which a humanized anti-CD3 molecule — that is, a monoclonal antibody called hOKT3γ1(Ala-Ala) that contains the binding region of OKT3 but a mutated Fc region that prevents it from binding to the Fc receptor — was used in patients with renal-allograft rejection demonstrated efficacy similar to that of OKT3 with markedly fewer side effects.14,15 On the basis of these observations, we initiated a randomized, controlled, phase 1–2 trial of this agent in patients with new-onset type 1 diabetes mellitus. In this report, we describe the results among patients who were followed for one year after treatment.

Methods

Study Patients

Patients between 7 1/2 and 30 years of age in whom type 1 diabetes mellitus had been diagnosed within the previous six weeks (or who had been discharged from the hospital within that period after receiving such a diagnosis) were eligible for participation. All patients had one or more of the following types of antibodies: anti-GAD (glutamic acid decarboxylase), anti–islet-cell antibody 512 (ICA512), and anti-insulin antibody. Patients were treated by their personal physicians, received at least three injections of short-acting or intermediate-acting insulin, and did not discontinue insulin therapy during the study period. The study was approved by the institutional review boards at Columbia Presbyterian Medical Center, the National Institute of Diabetes and Digestive and Kidney Diseases, the University of Utah, and the University of California at San Francisco. All patients or their parents provided written informed consent, and written assent was obtained from minor subjects.

Study Protocol

The data reported here were obtained between May 1999 and August 2001. Eligible patients were randomly assigned to the control group or the monoclonal-antibody group. Patients in the control group underwent metabolic and immunologic studies but did not receive monoclonal antibody and were not hospitalized. Blood samples were drawn for immunologic studies and measurement of glycosylated hemoglobin when the patient entered the study, and a four-hour mixed-meal tolerance test was performed after the morning dose of insulin and the previous evening's dose of long-acting insulin had been withheld.7

Nine patients in the monoclonal-antibody group were hospitalized, and the other three received monoclonal antibody on an outpatient basis. All 12 patients received a 14-day course of the anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) administered intravenously (1.42 μg per kilogram of body weight on day 1; 5.67 μg per kilogram on day 2; 11.3 μg per kilogram on day 3; 22.6 μg per kilogram on day 4; and 45.4 μg per kilogram on days 5 through 14); the doses were based on those previously used for treatment of transplant rejection.15 The dosing resulted in median peak and trough serum monoclonal-antibody levels of 133 ng per milliliter (range, 68 to 275) and 51 ng per milliliter (range, 23 to 255), respectively. Flow cytometry was used for the enumeration of CD4+ T cells, CD8+ T cells, and non–T cells and for coating and modulation of the CD3 molecule.15 Coating of CD3+ cells was maximal (mean [±SD] percentage reduction in fluorescence, 69.2±2.9) by day 12 of monoclonal-antibody treatment. Modulation of the CD3 molecule reached a peak level of 54.0±3.1 percent by day 14.

Patients underwent physical examinations, blood counts, and blood chemistries and were questioned about side effects weekly for two weeks after discharge and every two to three months thereafter. Glycosylated hemoglobin was measured and a mixed-meal tolerance test was performed every six months.

Statistical Analysis

C-peptide levels were measured by radioimmunoassay at the Diabetes Research and Training Center at the University of Chicago.16 The C-peptide response to the mixed meal was expressed as the total area under the response curve or the incremental area under the curve formed by subtracting the fasting C-peptide level from the response at each time point.7 A change in the response was considered to have occurred if the response differed by more than 7.5 percent from the response at study entry (7.5 percent being half of the interassay coefficient of variation for the C-peptide assay). Changes in insulin secretion were evaluated by examining the slope of the line described by the three data points (at study entry, 6 months, and 12 months).

Anti-GAD antibody, anti-ICA512, and anti-insulin antibody were measured with radiobinding assays.17 For genotyping at the HLA-DQA and DQB loci, direct sequencing of exon 2 polymorphisms was used after polymerase-chain-reaction amplification.18

Cytokines were measured in serum by enzyme-linked immunosorbent assay (ELISA) (BioSource and Immunotech). Anti-idiotype antibodies were identified by ELISA with the use of plate-bound OKT3 or by flow cytometry to measure the blockade of binding of OKT3 fluorescein isothiocyanate to CD3.19 Glycosylated hemoglobin levels were measured by latex-agglutination inhibition tests (DCA 2000, Bayer) or by affinity chromatography (Isolab) in the three patients treated at the National Institutes of Health.

Data are expressed as means ±SD. We used repeated-measures analysis of variance to compare the control group and the monoclonal-antibody group in terms of the response to the mixed-meal tolerance test, the glycosylated hemoglobin level, and the required dose of insulin. Comparisons between groups were made with the Mann–Whitney U test. Fisher's exact test was used to assess the effect of monoclonal-antibody treatment on the response to mixed-meal tolerance testing. Statistical analyses were performed with StatView software (SAS Institute).

Results

Enrollment of Study Patients

The average age of patients in the control group was slightly higher than that in the monoclonal-antibody group, but there were no significant differences between the two groups at entry (Table 1Table 1Characteristics of the Patients at Entry.). Autoantibodies against at least one type of biochemically defined autoantigen were present in all subjects.

Effects of Antibody Treatment on Circulating Lymphocytes

A transient reduction in the number of circulating lymphocytes occurred with monoclonal-antibody treatment. After the administration of the first full dose of monoclonal antibody on day 5, the absolute lymphocyte count reached a nadir of 26.5±9.0 percent of the base-line lymphocyte count. The changes in the absolute lymphocyte count were due to reductions in the numbers of CD4+ cells, CD8+ cells, and B cells (CD19+ cells) to 36.6±19.0 percent of their pretreatment levels. The reduction in the number of circulating lymphocytes was transient, however, and the number of circulating cells began to rise after the seventh day of treatment. By day 30 (two weeks after the last dose of the monoclonal antibody), the level of circulating lymphocytes reached 123.0±52.0 percent of the pretreatment level.

Release of Cytokines after Treatment

The levels of cytokines were measured in serum after the initial two doses of monoclonal antibody and after the first two full doses on days 5 and 6. Interleukin-6 was detectable in 8 of the patients treated with monoclonal antibody (range of levels, 14 to 225 pg per milliliter), and tumor necrosis factor α was detectable in all 12 patients (range of levels, 7 to 158 pg per milliliter). The circulating levels of these cytokines were maximal after the administration of the second dose of the monoclonal antibody but were considerably lower than levels previously reported in patients with the “cytokine-release syndrome” associated with the administration of OKT3; these levels were consistent with the mild clinical side effects.13 Interleukin-2 was not detectable in these patients, and interferon-γ was detectable in only one patient, whereas interleukin-5 was detected in the serum of nine of the antibody-treated patients (range of levels, 9 to 33 pg per milliliter) and interleukin-10 was detected in the serum of seven patients (range of levels, 5 to 316 pg per milliliter).

Side Effects of Antibody Treatment

Side effects of monoclonal-antibody infusions included mild and moderate fever in 9 of the 12 patients, generally on day 5; mild or moderate anemia in 9 of the 12 (which resolved after day 14); and nausea, vomiting, arthralgia, and headache in 1 patient each. A pruritic urticarial rash developed on the hands and occasionally the trunk and feet of 7 of the 12 patients. The rash appeared after the seventh day of treatment and resolved by day 30. A biopsy of this rash in two patients showed spongiosis consistent with eczematous dermatitis. There was no evidence of vasculitis. Antiidiotype antibodies developed in 6 of the 12 patients within the first month after treatment; but after six months, only 3 patients still had antibodies, and at one year, only 1 had detectable levels. There has been no evidence of long-term toxic effects up to two years after antibody treatment.

Monoclonal-Antibody Treatment and Insulin Production

Antibody treatment significantly reduced the decline in the incremental and total C-peptide responses (P=0.01 for both comparisons) (Table 2Table 2Changes in the Incremental and Total C-Peptide Responses during Mixed-Meal Tolerance Testing. and Figure 1Figure 1Changes from Study Entry to 12 Months in the Total C-Peptide Response to Mixed-Meal Tolerance Testing.). At the end of one year, the incremental C-peptide response in the monoclonal-antibody group was 109±74 percent of the response to the mixed-meal tolerance test at entry and the total C-peptide response was 103±53 percent of the base-line response, whereas the corresponding values in the control group were 42±35 percent and 49±33 percent of the base-line response. There was an average monthly decrease in the total C-peptide response of 5.52±1.30 nmol per liter per four-hour test in the control group, as compared with an average monthly increase of 0.20±1.86 nmol per liter per four-hour test in the monoclonal-antibody group (P=0.006). After one year, seven of the patients in the monoclonal-antibody group had no change or an increase (of more than 7.5 percent) from base line in the incremental response during the mixed-meal tolerance test; the other five had a decrease in the incremental response. By contrast, 11 of the 12 patients in the control group had a decrease in the incremental response (P=0.03). Nine of the 12 patients in the monoclonal-antibody group had no change or an increase in the total C-peptide response, whereas 10 of the 12 patients in the control group had a decrease in response (P=0.01).

Eleven of the 12 treated patients have been followed for more than 18 months. At 18 months, the mean incremental C-peptide response in these 11 patients was 90±82 percent of the pretreatment level, and the total C-peptide response was 74±39 percent of the base-line level. The incremental response was the same as the base-line response or greater in 6 of the 11 patients, and the total response was the same as the base-line response or greater in 5 of the 11 patients. By contrast, in 9 of the 12 controls studied, the incremental C-peptide response was 35±38 percent of the base-line level (P=0.07 for the comparison with the monoclonal-antibody group), and the total C-peptide response was 42±36 percent of the base-line level (P=0.06 for the comparison with the monoclonal-antibody group).

Metabolic Control of Diabetes

Antibody treatment resulted in a significant decrease in glycosylated hemoglobin levels (P=0.008). At study entry, the average glycosylated hemoglobin level was nonsignificantly higher in the monoclonal-antibody group, but the decline in glycosylated hemoglobin levels between base line and six months was greater in that group (P=0.01) (Table 3Table 3Effects of Treatment with the Monoclonal Antibody hOKT3γ1(Ala-Ala) on Metabolic Measures.). There were no severe hypoglycemic events in either group.

The improved glycemic control was not due to increased use of insulin in the monoclonal-antibody group. In fact, there was a significant decrease in the use of insulin in the monoclonal-antibody group as compared with the control group (P=0.03) (Table 3). After one year, the average insulin dose in the monoclonal-antibody group was below the level that is considered to indicate clinical remission (0.5 U per kilogram per day).20 Thus, monoclonal-antibody treatment resulted in improved metabolic control with reduced insulin usage during the first year after the diagnosis of type 1 diabetes mellitus.

Possible Predictors of Clinical Response

There were no differences between the patients with a response to monoclonal-antibody treatment and those with no response in terms of clinical presentation (including the presence or absence of patients with diabetic ketoacidosis), the titers of biochemically defined autoantibodies, the isotype subclasses of the autoantibodies, or the HLA-DQA1 and DQB1 genotypes. The mean fasting C-peptide level at study entry was 0.24±0.13 nmol per liter in subjects who had an increase or no change in the incremental C-peptide response to the mixed-meal tolerance test at six months, as compared with 0.12±0.09 nmol per liter in those who had a decline in the C-peptide response (P=0.13).

The pattern of T-cell repopulation after the nadir in the absolute lymphocyte count correlated with the response to monoclonal antibody. At 3 months (90 days), patients with a response to monoclonal-antibody treatment had a 68 percent increase in the absolute number of repopulating CD8+ T cells, which was reflected in a reduction in the ratio of CD4+ T cells to CD8+ T cells (Figure 2Figure 2Mean CD4+ and CD8+ T-Cell Counts in the Monoclonal-Antibody Group According to the Presence or Absence of a Response to Treatment.).

Discussion

Treatment of new-onset type 1 diabetes mellitus with a single course of a monoclonal antibody against CD3 that does not bind to the Fc receptor appears to have arrested the loss of insulin responses during the first year after diagnosis in most, but not all, of the 12 patients we studied. One year after treatment, two thirds of the antibody-treated patients had a C-peptide response to the mixed-meal tolerance test that was the same as or greater than their response at study entry. In contrast, there was a consistent decline in the C-peptide response in 10 of the 12 untreated patients. The decline among control patients is somewhat surprising, since many of these patients entered a clinical “honeymoon” that has been thought to reflect improved insulin secretion after diagnosis. However, our metabolic studies, which used a four-hour provocative test rather than more abbreviated protocols, challenge this notion and suggest that a relentless decline is the natural history of the disease in the majority of patients. At the time of study entry, the control group was slightly older, had lower glycosylated hemoglobin levels, and had greater responses to the mixed-meal tolerance test than the monoclonal-antibody group. These differences between the two groups, although not statistically significant, would tend to bias the results against an effect of the antibody treatment, since patients younger than 18 years of age have generally been found to have more aggressive disease than patients 18 years of age or older.21,22 Thus, the true antibody effect may have been greater than is apparent from the comparison of these two groups. Furthermore, even after 18 months, the C-peptide response to the mixed-meal tolerance test was the same as or greater than that at diagnosis in 6 of the 11 antibody-treated patients who had been followed for that long.

Accumulated clinical experience, as well as results from the Diabetes Control and Complications Trial23 and other studies,24,25 indicate that there is better metabolic control of type 1 diabetes mellitus in patients in whom some insulin secretion is retained. In the Diabetes Control and Complications Trial, a stimulated C-peptide level of more than 0.2 nmol per liter was associated with improved metabolic control, as reflected in the glycosylated hemoglobin level.23 It is not surprising, therefore, that the improved insulin secretion was accompanied by an improvement in the glycosylated hemoglobin level and a reduction in the insulin needs of patients treated with monoclonal antibody.

Antibody treatment had a sustained effect on the disease in the absence of continued administration of the monoclonal antibody. The effects of this monoclonal antibody on T cells differ from those of previously tested immunosuppressive agents and may account for the more sustained response. Other immunosuppressive agents, including cyclosporine, azathioprine, and prednisone, work by blocking the effector phases of immune responses by interfering with the production of cytokines, the proliferation of T cells, or both. Preclinical studies by Bluestone and colleagues26-28 suggested that antibody against CD3 that does not bind to the Fc receptor has selective effects on specific populations of T cells. It kills or causes unresponsiveness in T cells that produce interleukin-2 or interferon-γ (type 1 helper T [Th1] cells), whereas T cells that produce interleukin-10 or interleukin-4 (type 2 helper T [Th2] cells) may be stimulated by the monoclonal antibody.26-28 This effect is seen only in activated T cells and not in naive T cells. The presence of interleukin-10 and interleukin-5 — but not interferon-γ or interleukin-2 — in serum after monoclonal-antibody treatment is consistent with these observations. Studies involving animal models support the importance of Th1 responses in the pathogenesis of type 1 diabetes mellitus, suggesting a mechanism for the effect of monoclonal-antibody treatment.4,29-32 Clearly, the drug binds all T cells that express the CD3 molecule. Therefore, the selectivity observed among subpopulations of T cells may relate to quantitative or qualitative differences in response to the signal delivered by the monoclonal antibody. This may be analogous to the differential response to altered-peptide ligands by various subpopulations of T cells.33,34 Thus, the effect of monoclonal-antibody therapy may be to shift the autoimmune response toward production of protective (Th2) cytokines. The rash that developed in most patients, with histologic features similar to those of eczemoid lesions, might be mediated by Th2 responses.35

Subjects who had a response to the monoclonal-antibody treatment had an increase in the number of CD8+ T cells after treatment. Several reports have described subpopulations of CD8+ cells in rodents and humans that have immune-regulatory properties.36-38 Studies are under way to find cell-surface markers that can identify cells associated with a response to monoclonal-antibody treatment and that may indicate the presence of regulatory populations after such treatment.

We did not observe any changes in the titer or the isotypes of anti-GAD autoantibodies. It is possible that these autoantibody responses had already matured at the time of diagnosis and thus were not susceptible to change by circulating cytokines. Similarly, we failed to find an effect of monoclonal-antibody treatment on antirubella IgG titers (mean ratio of patient titers to standard titers at entry, 1.33±0.62; mean ratio at six months, 1.38±0.06), suggesting that established humoral responses were unaffected. Other immunologic markers, including HLA type and the titers and isotypes of autoantibodies, did not predict clinical response. The fasting C-peptide level was higher in the patients who had a response to treatment but was not an absolute predictor of a clinical response to the monoclonal antibody, as it was in the case of cyclosporine treatment of new-onset type 1 diabetes.5

Thus, treatment within the first six weeks after the onset of type 1 diabetes mellitus with a single course of anti-CD3 monoclonal antibody appeared to arrest the deterioration of insulin production in the majority of our 12 patients for at least the first year of disease. The mechanism of antibody action is under investigation, but we speculate that the monoclonal antibody may alter the immunologic response that causes type 1 diabetes mellitus, may induce a population of cells that can influence the disease process, or both.

Supported by grants from the National Institutes of Health (R01DK57846, U19A146132, M01 RR00645, M01 RR01271, and P60 DK20595) and the Juvenile Diabetes Research Foundation (Special Grant 4-1999-711 and Center Grant 4-1999-841). Dr. Bluestone has a financial interest in the monoclonal antibody hOKT3γ1(Ala-Ala) consisting of a patent application and a commercial agreement with Centocor and Johnson & Johnson Pharmaceuticals.

Source Information

From the Naomi Berrie Diabetes Center and the Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York (K.C.H., E.P.-R., L.T.); Pacific Northwest Research Institute, Seattle (W.H.); the University of Chicago, Chicago (J.A.A.); the University of Utah, Salt Lake City (D.D.); the Departments of Pediatrics (S.E.G.) and Medicine (J.A.B.), University of California at San Francisco, San Francisco; the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md. (D.M.H.); and the R.W. Johnson Pharmaceutical Research Institute, Raritan, N.J. (D.X., R.A.Z.).

Address reprint requests to Dr. Herold at Columbia University, 1150 St. Nicholas Ave., New York, NY 10032, or at kh318@columbia.edu.

References

References

1. 1

   Eisenbarth GS. Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med 1986;314:1360-1368
   Full Text | Web of Science | Medline

2. 2

   Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229[Erratum, Lancet 2001;358:766.]
   CrossRef | Web of Science | Medline

3. 3

   Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996;335:860-863[Erratum, N Engl J Med 1996;335:1778.]
   Free Full Text | Web of Science | Medline

4. 4

   Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998;55:1139-1149
   CrossRef | Web of Science | Medline

5. 5

   Bougneres PF, Carel JC, Castano L, et al. Factors associated with remission of type 1 diabetes in children treated with cyclosporine. N Engl J Med 1988;318:663-670
   Full Text | Web of Science | Medline

6. 6

   Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988;319:599-604
   Full Text | Web of Science | Medline

7. 7

   Skyler JS, Rabinovitch A. Cyclosporine in recent onset type I diabetes mellitus: effects on islet beta cell function. J Diabetes Complications 1992;6:77-88
   CrossRef | Medline

8. 8

   Stiller CR, Dupre J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984;223:1362-1367
   CrossRef | Web of Science | Medline

9. 9

   Parving HH, Tarnow L, Nielsen FS, et al. Cyclosporine nephrotoxicity in type 1 diabetic patients: a 7-year follow-up study. Diabetes Care 1999;22:478-483
   CrossRef | Web of Science | Medline

10. 10

    Herold KC, Bluestone JA, Montag AG, et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992;41:385-391
    CrossRef | Web of Science | Medline

11. 11

    Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158:2947-2954
    Web of Science | Medline

12. 12

    Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994;91:123-127
    CrossRef | Web of Science | Medline

13. 13

    Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantation 1990;49:697-702
    CrossRef | Web of Science | Medline

14. 14

    Woodle ES, Bluestone JA, Zivin RA, et al. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience. Transplant Proc 1998;30:1369-1370
    CrossRef | Web of Science | Medline

15. 15

    Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999;68:608-616
    CrossRef | Web of Science | Medline

16. 16

    Faber OK, Binder C, Markussen J, et al. Characterization of seven C-peptide antisera. Diabetes 1978;27:Suppl 1:170-177
    Web of Science | Medline

17. 17

    Woo W, LaGasse JM, Zhou Z, et al. A novel high-throughput method for accurate, rapid, and economical measurement of multiple type 1 diabetes autoantibodies. J Immunol Methods 2000;244:91-103
    CrossRef | Web of Science | Medline

18. 18

    Erlich H, Bugawan T, Begovich AB, et al. HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. Eur J Immunogenet 1991;18:33-55
    CrossRef | Medline

19. 19

    Chatenoud L. Humoral immune response against OKT3. Transplant Proc 1993;25:Suppl 1:68-73
    Web of Science | Medline

20. 20

    Yilmaz MT, Devrim AS, Biyal F, et al. Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results. Diabetes Res Clin Pract 1993;19:151-162
    CrossRef | Web of Science | Medline

21. 21

    The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30-36
    CrossRef | Web of Science | Medline

22. 22

    Karjalainen J, Salmela P, Ilonen J, Surcel HM, Knip M. A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 1989;320:881-886
    Full Text | Web of Science | Medline

23. 23

    The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: a randomized, controlled trial. Ann Intern Med 1998;128:517-523
    Web of Science | Medline

24. 24

    Sjoberg S, Gjotterberg M, Berglund L, Moller E, Ostman J. Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type I (insulin-dependent) diabetes mellitus. J Diabetes Complications 1991;5:18-22
    CrossRef

25. 25

    Grajwer LA, Pildes RS, Horwitz DL, Rubenstein AH. Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity. J Pediatr 1977;90:42-48
    CrossRef | Web of Science | Medline

26. 26

    Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997;185:1413-1422
    CrossRef | Web of Science | Medline

27. 27

    Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998;160:4841-4849
    Web of Science | Medline

28. 28

    Smith JA, Bluestone JA. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr Opin Immunol 1997;9:648-654
    CrossRef | Web of Science | Medline

29. 29

    Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995;268:1185-1188
    CrossRef | Web of Science | Medline

30. 30

    Herold KC, Vezys V, Sun Q, et al. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol 1996;156:3521-3527
    Web of Science | Medline

31. 31

    Zipris D, Greiner DL, Malkani S, Whalen B, Mordes JP, Rossini AA. Cytokine gene expression in islets and thyroids of BB rats: IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats. J Immunol 1996;156:1315-1321
    Web of Science | Medline

32. 32

    Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178:87-99
    CrossRef | Web of Science | Medline

33. 33

    Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996;14:1-27
    CrossRef | Web of Science | Medline

34. 34

    Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993;363:156-159
    CrossRef | Web of Science | Medline

35. 35

    Izuhara K, Shirakawa T. Signal transduction via the interleukin-4 receptor and its correlation with atopy. Int J Mol Med 1999;3:3-10
    Web of Science | Medline

36. 36

    Ware R, Jiang H, Braunstein N, et al. Human CD8+ T lymphocyte clones specific for T cell receptor V beta families expressed on autologous CD4+ T cells. Immunity 1995;2:177-184
    CrossRef | Web of Science | Medline

37. 37

    Liu Z, Tugulea S, Cortesini R, Suciu-Foca N. Specific suppression of T helper alloreactivity by allo-MHD class I-restricted CD8+CD28- T cells. Int Immunol 1998;10:775-783
    CrossRef | Web of Science | Medline

38. 38

    Jiang S, Tugulea S, Pennesi G, et al. Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro. Hum Immunol 1998;59:690-699
    CrossRef | Web of Science | Medline

Citing Articles (394)

Citing Articles

1. 1

   Tony L.H. Chu, Qiunong Guan, Christopher Y.C. Nguan, Caigan Du. (2013) Halofuginone suppresses T cell proliferation by blocking proline uptake and inducing cell apoptosis. International Immunopharmacology 16:4, 414-423
   

2. 2

   D. A. Schneider, A. M. Kretowicz, M. G. von Herrath. (2013) Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation. Diabetes, Obesity and Metabolism 15:7, 581-592
   

3. 3

   M. Pihl, L. Åkerman, S. Axelsson, M. Chéramy, M. Hjorth, R. Mallone, J. Ludvigsson, R. Casas. (2013) Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes. Clinical & Experimental Immunology 172:3, 394-402
   

4. 4

   Antoinette Moran, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks, Philip Raskin, Srinath Sanda, Desmond Schatz, Diane K Wherrett, Darrell M Wilson, Jeffrey P Krischer, Jay S Skyler, Linda Pickersgill, Eelco de Koning, Anette-G Ziegler, Bernhard Böehm, Klaus Badenhoop, Nanette Schloot, Jens Friis Bak, Paolo Pozzilli, Didac Mauricio, Marc Y Donath, Luis Castaño, Ana Wägner, Hans Henrik Lervang, Hans Perrild, Thomas Mandrup-Poulsen. (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. The Lancet 381:9881, 1905-1915
   

5. 5

   Tobias Boettler, Philippe P. Pagni, Rachel Jaffe, Yang Cheng, Peter Zerhouni, Matthias von Herrath. (2013) The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes. Journal of Autoimmunity
   

6. 6

   Hilary R. Thomas, Stephen E. Gitelman. (2013) Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatric Diabetesn/a-n/a
   

7. 7

   M. von Herrath, M. Peakman, B. Roep. (2013) Progress in immune-based therapies for type 1 diabetes. Clinical & Experimental Immunology 172:2, 186-202
   

8. 8

   Jordan Sugarman, Sue Tsai, Pere Santamaria, Anmar Khadra. (2013) Quantifying the importance of pMHC valency, total pMHC dose and frequency on nanoparticle therapeutic efficacy. Immunology and Cell Biology 91:5, 350-359
   

9. 9

   Anastasia G. Daifotis, Scott Koenig, Lucienne Chatenoud, Kevan C. Herold. (2013) Anti-CD3 clinical trials in type 1 diabetes mellitus. Clinical Immunology
   

10. 10

    Wenhao Chen, Aini Xie, Lawrence Chan. (2013) Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Translational Research 161:4, 217-229
    

11. 11

    Lindsey E. Padgett, Katarzyna A. Broniowska, Polly A. Hansen, John A. Corbett, Hubert M. Tse. (2013) The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Annals of the New York Academy of Sciences 1281:1, 16-35
    

12. 12

    Aaron Martin, Roland M. Tisch, Daniel R. Getts. (2013) Manipulating T cell-mediated pathology: Targets and functions of monoclonal antibody immunotherapy. Clinical Immunology
    

13. 13

    Kevan C. Herold, Dario A. A. Vignali, Anne Cooke, Jeffrey A. Bluestone. (2013) Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nature Reviews Immunology 13:4, 243-256
    

14. 14

    Ana B. Bueno, Ana M. Castaño, Ángel Rodríguez. Diabetes Drugs. In: Drug Discovery. John Wiley & Sons, Inc., 2013:205-243.
    

15. 15

    Aaron W. Michels. (2013) Targeting the Trimolecular Complex. Clinical Immunology
    

16. 16

    K. C. Herold, S. E. Gitelman, S. M. Willi, P. A. Gottlieb, F. Waldron-Lynch, L. Devine, J. Sherr, S. M. Rosenthal, S. Adi, M. Y. Jalaludin, A. W. Michels, J. Dziura, J. A. Bluestone. (2013) Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 56:2, 391-400
    

17. 17

    P. George, R. J. McCrimmon. (2013) Potential role of non-insulin adjunct therapy in Type 1 diabetes. Diabetic Medicine 30:2, 179-188
    

18. 18

    Denise L Faustman. (2013) EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop?. Expert Review of Clinical Immunology 9:2, 95-97
    

19. 19

    Ken T. Coppieters, Leonard C. Harrison, Matthias G. von Herrath. (2013) Trials in type 1 diabetes: Antigen-specific therapies. Clinical Immunology
    

20. 20

    S. Alice Long, Jane H. Buckner, Carla J. Greenbaum. (2013) IL-2 therapy in type 1 diabetes: “Trials” and tribulations. Clinical Immunology
    

21. 21

    B. J. Loechelt, D. Boulware, M. Green, L. R. Baden, P. Gottlieb, H. Krause-Steinrauf, A. Weinberg, . (2013) Epstein-Barr and Other Herpesvirus Infections in Patients With Early Onset Type 1 Diabetes Treated With Daclizumab and Mycophenolate Mofetil. Clinical Infectious Diseases 56:2, 248-254
    

22. 22

    Albert J. Czaja. (2013) Management of Recalcitrant Autoimmune Hepatitis. Current Hepatitis Reports
    

23. 23

    Åke Lernmark, Helena Elding Larsson. (2013) Immune therapy in type 1 diabetes mellitus. Nature Reviews Endocrinology 9:2, 92-103
    

24. 24

    Georg H. Stummvoll, Josef S. Smolen. Investigational Agents and Future Therapy for SLE. In: Dubois' Lupus Erythematosus and Related Syndromes. Elsevier, 2013:659-665.
    

25. 25

    Leslie J. Raffel, Mark O. Goodarzi. Diabetes Mellitus. In: Emery and Rimoin's Principles and Practice of Medical Genetics. Elsevier, 2013:1-58.
    

26. 26

    D. Dabelea, E. J. Mayer-Davis, J. S. Andrews, L. M. Dolan, C. Pihoker, R. F. Hamman, C. Greenbaum, S. Marcovina, W. Fujimoto, B. Linder, G. Imperatore, R. D’Agostino. (2012) Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study. Diabetologia 55:12, 3359-3368
    

27. 27

    George Vlad, Nicole Suciu-Foca. (2012) Induction of antigen-specific human T suppressor cells by membrane and soluble ILT3. Experimental and Molecular Pathology 93:3, 294-301
    

28. 28

    Lirong Li, Weiqiong Gu, Dalong Zhu. (2012) Novel therapy for type 1 diabetes: Autologous hematopoietic stem cell transplantation. Journal of Diabetes 4:4, 332-337
    

29. 29

    T. Alkhamis, J. Barbic, T. Crnogorac-Jurcevic, R. E. Greenlaw, M. Peakman, S. Jurcevic. (2012) Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice. Clinical & Experimental Immunology 170:2, 139-148
    

30. 30

    Barbara Brooks-Worrell, Radhika Narla, Jerry P. Palmer. (2012) Biomarkers and immune-modulating therapies for Type 2 diabetes. Trends in Immunology 33:11, 546-553
    

31. 31

    S. You, J. Zuber, C. Kuhn, M. Baas, F. Valette, V. Sauvaget, S. Sarnacki, B. Sawitzki, J.-F. Bach, H.-D. Volk, L. Chatenoud. (2012) Induction of Allograft Tolerance by Monoclonal CD3 Antibodies: A Matter of Timing. American Journal of Transplantation 12:11, 2909-2919
    

32. 32

    James A. Thompson, Daniel Perry, Todd M. Brusko. (2012) Autologous Regulatory T Cells for the Treatment of Type 1 Diabetes. Current Diabetes Reports 12:5, 623-632
    

33. 33

    F. Baeke, T. L. Belle, T. Takiishi, L. Ding, H. Korf, J. Laureys, C. Gysemans, C. Mathieu. (2012) Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes. Diabetologia 55:10, 2723-2732
    

34. 34

    F. Waldron-Lynch, S. Deng, P. Preston-Hurlburt, O. Henegariu, K. C. Herold. (2012) Analysis of Human Biologics With a Mouse Skin Transplant Model in Humanized Mice. American Journal of Transplantation 12:10, 2652-2662
    

35. 35

    S.L. Malcolm, E.L. Smith, T. Bourne, S. Shaw. (2012) A humanised mouse model of cytokine release: Comparison of CD3-specific antibody fragments. Journal of Immunological Methods 384:1-2, 33-42
    

36. 36

    Albert J. Czaja. (2012) Advances in the Current Treatment of Autoimmune Hepatitis. Digestive Diseases and Sciences 57:8, 1996-2010
    

37. 37

    Jan Novak, Lucie Novakova. (2012) Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells. Clinical and Experimental Medicine
    

38. 38

    Christopher S. McAllister, Martin F. Kagnoff. (2012) The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet. Seminars in Immunopathology 34:4, 581-600
    

39. 39

    Smita Gupta. (2012) Immunotherapies in Diabetes Mellitus Type 1. Medical Clinics of North America 96:3, 621-634
    

40. 40

    Tatiana Takiishi, Hannelie Korf, Tom L. Van Belle, Sofie Robert, Fabio A. Grieco, Silvia Caluwaerts, Letizia Galleri, Isabella Spagnuolo, Lothar Steidler, Karolien Van Huynegem, Pieter Demetter, Clive Wasserfall, Mark A. Atkinson, Francesco Dotta, Pieter Rottiers, Conny Gysemans, Chantal Mathieu. (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. Journal of Clinical Investigation
    

41. 41

    Jay S. Skyler. Type 1 Diabetes Mellitus: Immune Intervention. In: ATTD 2011 Yearbook. Wiley-Blackwell, 2012:157-173.
    

42. 42

    Xiu-ying Yang, Dina Levi, Houria Ounissi-Benkalha, Xiao-yan Yu, Hui-qi Qu, Constantin Polychronakos, Guan-hua Du. (2012) Screening for novel lead compounds increasing insulin expression in medullary thymic epithelial cells. European Journal of Pharmacology
    

43. 43

    Eliana Mariño, Shane T. Grey. (2012) B cells as effectors and regulators of autoimmunity. Autoimmunity1-1
    

44. 44

    Mona Landin-Olsson, Charlotte Erlanson-Albertsson. (2012) Immunotherapy for Type 1 diabetes: past and future. Diabetes Management 2:2, 139-147
    

45. 45

    Jay S. Skyler. (2012) Type 1 diabetes mellitus: immune intervention. International Journal of Clinical Practice 66, 56-61
    

46. 46

    James E. Tooley, Frank Waldron-Lynch, Kevan C. Herold. (2012) New and future immunomodulatory therapy in type 1 diabetes. Trends in Molecular Medicine
    

47. 47

    F. Waldron-Lynch, O. Henegariu, S. Deng, P. Preston-Hurlburt, J. Tooley, R. Flavell, K. C. Herold. (2012) Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients. Science Translational Medicine 4:118, 118ra12-118ra12
    

48. 48

    Andre Pires da Cunha, Howard L. Weiner. (2012) Induction of Immunological Tolerance by Oral Anti-CD3. Clinical and Developmental Immunology 2012, 1-5
    

49. 49

    Yong Zhao, Zhaoshun Jiang, Tingbao Zhao, Mingliang Ye, Chengjin Hu, Zhaohui Yin, Heng Li, Ye Zhang, Yalin Diao, Yunxiang Li, Yingjian Chen, Xiaoming Sun, Mary Beth Fisk, Randal Skidgel, Mark Holterman, Bellur Prabhakar, Theodore Mazzone. (2012) Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Medicine 10:1, 3
    

50. 50

    Thomas Y. Ma, James M. Anderson, Jerrold R. Turner. Tight Junctions and the Intestinal Barrier. In: Physiology of the Gastrointestinal Tract, Two Volume Set. Elsevier, 2012:1043-1088.
    

51. 51

    Hugo Tadeu Metidieri, Rafael Dias Mancio, Éber Emanuel Mayoral, Fernanda Alvarez Rojas, Luis Antonio Peroni, Alan Telles Ferri, Edmir Américo Lourenço, Eduardo José Caldeira. (2012) Effects of anti-CD3 monoclonal antibody in salivary glands of spontaneously diabetic mice. Microscopy Research and Techniquen/a-n/a
    

52. 52

    David E.R. Sutherland, Angelika C. Gruessner, Bernhard J. Hering, Rainer W.G. Gruessner. Pancreas and Islet Cell Transplantation. In: Pediatric Surgery. Elsevier, 2012:631-641.
    

53. 53

    O. Kordonouri. (2011) Diabetesprävention bei Kindern. Der Diabetologe
    

54. 54

    Mary Pat Gallagher, Robin S. Goland, Carla J. Greenbaum. (2011) Making progress: preserving beta cells in type 1 diabetes. Annals of the New York Academy of Sciences 1243:1, 119-134
    

55. 55

    Jaime M. Realsen, H. Peter Chase. (2011) Recent Advances in the Prevention of Hypoglycemia in Type 1 Diabetes. Diabetes Technology & Therapeutics 13:12, 1177-1186
    

56. 56

    C.-R. Li, B. J. G. Baaten, L. M. Bradley. (2011) Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes. Journal of Molecular Cell Biology
    

57. 57

    Gonnie M. Alkemade, Robert Hilbrands, Evy Vandemeulebroucke, Daniel Pipeleers, Herman Waldmann, Chantal Mathieu, Bart Keymeulen, Bart O. Roep. (2011) Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. Diabetes/Metabolism Research and Reviews 27:8, 925-927
    

58. 58

    Miguel Barajas. (2011) Estrategias de terapia celular para el tratamiento de la diabetes tipo 1: dónde estamos y qué podemos esperar. Avances en Diabetología
    

59. 59

    Bart O Roep, Mark Peakman. (2011) Diabetogenic T lymphocytes in human Type 1 diabetes. Current Opinion in Immunology
    

60. 60

    Qiang Peng, Zhi-Rong Zhang, Tao Gong, Guo-Qiang Chen, Xun Sun. (2011) A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. Biomaterials
    

61. 61

    Ben Sprangers, Bart Van der Schueren, Pieter Gillard, Chantal Mathieu. (2011) Otelixizumab in the treatment of Type 1 diabetes mellitus. Immunotherapy 3:11, 1303-1316
    

62. 62

    Bhagirath Singh, Enayat Nikoopour, Katrina Huszarik, John F. Elliott, Anthony M. Jevnikar. (2011) Immunomodulation and Regeneration of Islet Beta Cells by Cytokines in Autoimmune Type 1 Diabetes. Journal of Interferon & Cytokine Research 31:10, 711-719
    

63. 63

    Diane K. Wherrett, Denis Daneman. (2011) Prevention of Type 1 Diabetes. Pediatric Clinics of North America 58:5, 1257-1270
    

64. 64

    Christian Seifarth, Leonie Littmann, Yazid Resheq, Susanne Rössner, Andreas Goldwich, Nadine Pangratz, Franz Kerek, Alexander Steinkasserer, Elisabeth Zinser. (2011) MCS-18, a novel natural plant product prevents autoimmune diabetes. Immunology Letters 139:1-2, 58-67
    

65. 65

    Dario Tuccinardi, Elvira Fioriti, Silvia Manfrini, Eugenio D'Amico, Paolo Pozzilli. (2011) DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes. Expert Opinion on Biological Therapy 11:9, 1233-1240
    

66. 66

    Raymond S. Douglas, Shivani Gupta. (2011) The pathophysiology of thyroid eye disease. Current Opinion in Ophthalmology 22:5, 385-390
    

67. 67

    Lucienne Chatenoud. (2011) Diabetes: Type 1 diabetes mellitus—a door opening to a real therapy?. Nature Reviews Endocrinology 7:10, 564-566
    

68. 68

    K. C. Herold, J. A. Bluestone. (2011) Type 1 Diabetes Immunotherapy: Is the Glass Half Empty or Half Full?. Science Translational Medicine 3:95, 95fs1-95fs1
    

69. 69

    Gillian M. Bell, Gary Reynolds, John D. Isaacs. (2011) Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. Nature Reviews Rheumatology 7:9, 507-516
    

70. 70

    Aaron W. Michels, Matthias von Herrath. (2011) 2011 Update. Current Opinion in Endocrinology, Diabetes and Obesity 18:4, 235-240
    

71. 71

    Sadaki Asari, Shin Itakura, Jeffrey Rawson, Taihei Ito, Ivan Todorov, Indu Nair, Jonathan Shintaku, Chih-Pin Liu, Fouad Kandeel, Yoko S. Mullen. (2011) Mesenchymal Stem Cells Facilitate Mixed Hematopoietic Chimerism Induction and Prevent Onset of Diabetes in Nonobese Diabetic Mice. Pancreas 40:6, 846-854
    

72. 72

    Lola Weiss, Steve Bernstein, Richard Jones, Ravi Amunugama, David Krizman, Lellean JeBailey, Osnat Hazan, Janna Yachtin, Reut Shiner, Israel Reibstein, Elizabeth Triche, Shimon Slavin, Reuven Or, Eytan R. Barnea. (2011) Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice. Endocrine 40:1, 41-54
    

73. 73

    Samuel W. Hall, Anne Cooke. (2011) Autoimmunity and inflammation: murine models and translational studies. Mammalian Genome 22:7-8, 377-389
    

74. 74

    Nicole Sherry, William Hagopian, Johnny Ludvigsson, Sunil M Jain, Jack Wahlen, Robert J Ferry, Bruce Bode, Stephen Aronoff, Christopher Holland, David Carlin, Karen L King, Ronald L Wilder, Stanley Pillemer, Ezio Bonvini, Syd Johnson, Kathryn E Stein, Scott Koenig, Kevan C Herold, Anastasia G Daifotis. (2011) Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. The Lancet 378:9790, 487-497
    

75. 75

    Jean-François Bach. (2011) Anti-CD3 antibodies for type 1 diabetes: beyond expectations. The Lancet 378:9790, 459-460
    

76. 76

    Wan-Fai Ng, Simon J Bowman. (2011) Biological therapies in primary Sjögren's syndrome. Expert Opinion on Biological Therapy 11:7, 921-936
    

77. 77

    Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi, Antoinette Moran, Philip Raskin, Henry Rodriguez, William E Russell, Desmond Schatz, Diane Wherrett, Darrell M Wilson, Jeffrey P Krischer, Jay S Skyler. (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. The Lancet 378:9789, 412-419
    

78. 78

    KARSTEN BUSCHARD. (2011) What causes type 1 diabetes? Lessons from animal models. APMIS 119, 1-19
    

79. 79

    Diane K Wherrett, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks, Roshanak Monzavi, Antoinette Moran, Tihamer Orban, Jerry P Palmer, Philip Raskin, Henry Rodriguez, Desmond Schatz, Darrell M Wilson, Jeffrey P Krischer, Jay S Skyler. (2011) Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. The Lancet 378:9788, 319-327
    

80. 80

    Vitaly Ablamunits, Octavian Henegariu, Paula Preston-Hurlburt, Kevan C. Herold. (2011) NKG2A is a marker for acquisition of regulatory function by human CD8 ⁺ T cells activated with anti-CD3 antibody. European Journal of Immunology 41:7, 1832-1842
    

81. 81

    Bechara Mfarrej, Mary Keir, Shirine Dada, Subbulaxmi Trikudanathan, Mohamed H. Sayegh, Arlene H. Sharpe, Indira Guleria. (2011) Anti-CD3 mAb treatment cures PDL1−/−.NOD mice of diabetes but precipitates fatal myocarditis. Clinical Immunology 140:1, 47-53
    

82. 82

    Frank Waldron-Lynch, Kevan C. Herold. (2011) Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nature Reviews Drug Discovery 10:6, 439-452
    

83. 83

    Jean-François Bach, Lucienne Chatenoud. (2011) A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. Seminars in Immunology 23:3, 174-181
    

84. 84

    Aaron W. Michels, George S. Eisenbarth. (2011) Immune intervention in type 1 diabetes. Seminars in Immunology 23:3, 214-219
    

85. 85

    B S Nikolajczyk, M Jagannathan-Bogdan, H Shin, R Gyurko. (2011) State of the union between metabolism and the immune system in type 2 diabetes. Genes and Immunity 12:4, 239-250
    

86. 86

    Manuela Battaglia, Maria-Grazia Roncarolo. (2011) Immune intervention with T regulatory cells: Past lessons and future perspectives for type 1 diabetes. Seminars in Immunology 23:3, 182-194
    

87. 87

    Eliana Mariño, Pablo A. Silveira, Jessica Stolp, Shane T. Grey. (2011) B cell-directed therapies in type 1 diabetes. Trends in Immunology 32:6, 287-294
    

88. 88

    Gerald T. Nepom, E. William St. Clair, Laurence A. Turka. (2011) Challenges in the pursuit of immune tolerance. Immunological Reviews 241:1, 49-62
    

89. 89

    Jeffrey A. Bluestone. (2011) Mechanisms of tolerance. Immunological Reviews 241:1, 5-19
    

90. 90

    Pieter Gillard, Chantal Mathieu. (2011) Immune and cell therapy in type 1 diabetes: too little too late?. Expert Opinion on Biological Therapy 11:5, 609-621
    

91. 91

    Emi Nishida, Chen Chen, Akimichi Morita, Jun Shimizu. (2011) Inhibition of T cell activation through down-regulation of TCR-CD3 expression mediated by an anti-CD90 Ab. Immunology Letters 136:2, 163-170
    

92. 92

    Mohamed Mabed. (2011) The Potential Utility of Bone Marrow or Umbilical Cord Blood Transplantation For the Treatment of Type I Diabetes Mellitus. Biology of Blood and Marrow Transplantation 17:4, 455-464
    

93. 93

    Chiara Guglielmi, Paolo Pozzilli. Early Diagnosis of Type 1 Diabetes: Useful or a Phyrrhic Victory?. In: Clinical Dilemmas in Diabetes. Wiley-Blackwell, 2011:11-21.
    

94. 94

    Alba E Morales, Kathryn M Thrailkill. (2011) GAD-alum immunotherapy in Type 1 diabetes mellitus. Immunotherapy 3:3, 323-332
    

95. 95

    D. Bresson, M. von Herrath. (2011) Humanizing Animal Models: A Key to Autoimmune Diabetes Treatment. Science Translational Medicine 3:68, 68ps4-68ps4
    

96. 96

    C. Kuhn, S. You, F. Valette, G. Hale, P. van Endert, J.-F. Bach, H. Waldmann, L. Chatenoud. (2011) Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance. Science Translational Medicine 3:68, 68ra10-68ra10
    

97. 97

    Amaya Oyarzún, Lydia Lera, Ethel Codner, Elena Carrasco, Francisco Pérez-Bravo. (2011) High concentrations of anti-caspase-8 antibodies in Chilean patients with type 1 diabetes. Immunobiology 216:1-2, 208-212
    

98. 98

    Brett Phillips, Massimo Trucco, Nick Giannoukakis. (2011) Current State of Type 1 Diabetes Immunotherapy: Incremental Advances, Huge Leaps, or More of the Same?. Clinical and Developmental Immunology 2011, 1-18
    

99. 99

    George S. Eisenbarth, John B. Buse. Type 1 Diabetes Mellitus. In: Williams Textbook of Endocrinology. Elsevier, 2011:1436-1461.
    

100. 100

     Tobias Boettler, Matthias von Herrath. (2010) Immunotherapy of type 1 diabetes — How to rationally prioritize combination therapies in T1D. International Immunopharmacology 10:12, 1491-1495
     

101. 101

     Sylvaine You, Lucienne Chatenoud. (2010) New generation CD3 monoclonal antibodies: are we ready to have them back in clinical transplantation?. Current Opinion in Organ Transplantation 15:6, 720-724
     

102. 102

     Jeffrey A. Bluestone, Hugh Auchincloss, Gerald T. Nepom, Daniel Rotrosen, E. William St. Clair, Laurence A. Turka. (2010) The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nature Reviews Immunology 10:11, 797-803
     

103. 103

     S. I. Mannering, F. S. Wong, I. Durinovic-Belló, B. Brooks-Worrell, T. I. Tree, C. M. Cilio, N. C. Schloot, R. Mallone, . (2010) Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes. Clinical & Experimental Immunology 162:2, 197-209
     

104. 104

     Geoff Hale, Peppy Rebello, Ibrahim Al Bakir, Emma Bolam, Pawel Wiczling, William J. Jusko, Evy Vandemeulebroucke, Bart Keymeulen, Chantal Mathieu, Annette-G Ziegler, Lucienne Chatenoud, Herman Waldmann. (2010) Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes. The Journal of Clinical Pharmacology 50:11, 1238-1248
     

105. 105

     Vitaly Ablamunits, Brygida Bisikirska, Kevan C. Herold. (2010) Acquisition of regulatory function by human CD8+ T cells treated with anti-CD3 antibody requires TNF. European Journal of Immunology 40:10, 2891-2901
     

106. 106

     Caroline B. Sangan, David Tosh. (2010) A new paradigm in cell therapy for diabetes: Turning pancreatic α-cells into β-cells. BioEssays 32:10, 881-884
     

107. 107

     E. J. Wehrens, F. van Wijk, S. T. Roord, S. Albani, B. J. Prakken. (2010) Treating arthritis by immunomodulation: is there a role for regulatory T cells?. Rheumatology 49:9, 1632-1644
     

108. 108

     Douglas O. Sobel, Annette Henzke, Val Abbassi. (2010) Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetologica 47:3, 243-250
     

109. 109

     J. Nishio, M. Feuerer, J. Wong, D. Mathis, C. Benoist. (2010) Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. Journal of Experimental Medicine 207:9, 1879-1889
     

110. 110

     Faye A.H. Cooles, John D. Isaacs. (2010) Treating to re-establish tolerance in inflammatory arthritis – lessons from other diseases. Best Practice & Research Clinical Rheumatology 24:4, 497-511
     

111. 111

     Helena Elding Larsson, Ahmed J. Delli, Sten-A. Ivarsson, Åke Lernmark. Future Drug Treatment for Type 1 Diabetes. In: Textbook of Diabetes. Wiley-Blackwell, 2010:999-1016.
     

112. 112

     Albert J. Czaja, Michael P. Manns. (2010) Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis. Gastroenterology 139:1, 58-72.e4
     

113. 113

     Robert B. Nussenblatt, Bibiana Bielekova, Richard Childs, Alan Krensky, Warren Strober, Giorgio Trinchieri, . (2010) National Institutes of Health Center for Human Immunology Conference, September 2009. Annals of the New York Academy of Sciences 1200, E1-E23
     

114. 114

     Flavia Serpieri, Andre Inocencio, Jose Marcelino Oliveira, Alécio A. Pimenta, Angélica Garbuio, Jorge Kalil, Marcelo M. Brigido, Ana Maria Moro. (2010) Comparison of Humanized IgG and FvFc Anti-CD3 Monoclonal Antibodies Expressed in CHO Cells. Molecular Biotechnology 45:3, 218-225
     

115. 115

     Takashi Arai, Hiroaki Moriyama, Mami Shimizu, Hirotomo Sasaki, Minoru Kishi, Yasuyo Okumachi, Hisafumi Yasuda, Kenta Hara, Koichi Yokono, Masao Nagata. (2010) Administration of a determinant of preproinsulin can induce regulatory T cells and suppress anti-islet autoimmunity in NOD mice. Clinical Immunology 136:1, 74-82
     

116. 116

     Maria Koulmanda, Terry B Strom. (2010) T-cell-directed treatment strategies for Type 1 diabetes and the confounding role of inflammation. Immunotherapy 2:4, 431-436
     

117. 117

     Denise Faustman, Miriam Davis. (2010) TNF receptor 2 pathway: drug target for autoimmune diseases. Nature Reviews Drug Discovery 9:6, 482-493
     

118. 118

     Chang-Qing Xia, Anna Chernatynskaya, Yimu Lai, Kim A. Campbell, Michael J. Clare-Salzler. (2010) Experimental extracorporeal photopheresis therapy significantly delays the development of diabetes in non-obese diabetic mice. Clinical Immunology 135:3, 374-383
     

119. 119

     Vibhavari M. Naik, Milind N. Naik, Robert A. Goldberg, Terry J. Smith, Raymond S. Douglas. (2010) Immunopathogenesis of Thyroid Eye Disease: Emerging Paradigms. Survey of Ophthalmology 55:3, 215-226
     

120. 120

     L. Steinman. (2010) Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity. Journal of Internal Medicine 267:5, 441-451
     

121. 121

     Aaron W. Michels, Peter A. Gottlieb. (2010) Autoimmune polyglandular syndromes. Nature Reviews Endocrinology 6:5, 270-277
     

122. 122

     Andrew C. Chan, Paul J. Carter. (2010) Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews Immunology 10:5, 301-316
     

123. 123

     J. B. Matthews, T. P. Staeva, P. L. Bernstein, M. Peakman, M. Von Herrath, . (2010) Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clinical & Experimental Immunology 160:2, 176-184
     

124. 124

     Matthias von Herrath. (2010) Combination therapies for Type 1 diabetes: why not now?. Immunotherapy 2:3, 289-291
     

125. 125

     Fabrizio Thorel, Virginie Népote, Isabelle Avril, Kenji Kohno, Renaud Desgraz, Simona Chera, Pedro L. Herrera. (2010) Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss. Nature 464:7292, 1149-1154
     

126. 126

     Mark R Rigby. (2010) The role of the physician–scientist in bridging basic and clinical research in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 17:2, 131-142
     

127. 127

     B. Keymeulen, M. Walter, C. Mathieu, L. Kaufman, F. Gorus, R. Hilbrands, E. Vandemeulebroucke, U. Velde, L. Crenier, C. Block, S. Candon, H. Waldmann, A. G. Ziegler, L. Chatenoud, D. Pipeleers. (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53:4, 614-623
     

128. 128

     Xunrong Luo, Kevan C. Herold, Stephen D. Miller. (2010) Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?. Immunity 32:4, 488-499
     

129. 129

     Brian Stadinski, John Kappler, George S. Eisenbarth. (2010) Molecular Targeting of Islet Autoantigens. Immunity 32:4, 446-456
     

130. 130

     Pere Santamaria. (2010) The Long and Winding Road to Understanding and Conquering Type 1 Diabetes. Immunity 32:4, 437-445
     

131. 131

     , J. Grijse, M. Asanghanwa, B. Nouthe, N. Albrecher, P. Goubert, I. Vermeulen, S. Meeren, K. Decochez, I. Weets, B. Keymeulen, V. Lampasona, J. Wenzlau, J. C. Hutton, D. Pipeleers, F. K. Gorus. (2010) Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 53:3, 517-524
     

132. 132

     Sanja Glisic, Sarah Ehlenbach, Parthav Jailwala, Jill Waukau, Srikanta Jana, Soumitra Ghosh. (2010) Inducible regulatory T cells (iTregs) from recent-onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls. Cell and Tissue Research 339:3, 585-595
     

133. 133

     Lucienne Chatenoud. (2010) Immune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies?. Nature Reviews Endocrinology 6:3, 149-157
     

134. 134

     Cristina Aguayo-Mazzucato, Susan Bonner-Weir. (2010) Stem cell therapy for type 1 diabetes mellitus. Nature Reviews Endocrinology 6:3, 139-148
     

135. 135

     B. Keymeulen, S. Candon, S. Fafi-Kremer, A. Ziegler, M. Leruez-Ville, C. Mathieu, E. Vandemeulebroucke, M. Walter, L. Crenier, E. Thervet, C. Legendre, D. Pierard, G. Hale, H. Waldmann, J.-F. Bach, J. M. Seigneurin, D. Pipeleers, L. Chatenoud. (2010) Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 115:6, 1145-1155
     

136. 136

     Simona Cernea, Kevan C. Herold. (2010) Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clinical Immunology 134:2, 121-129
     

137. 137

     Bart O. Roep, Mark Peakman. (2010) Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nature Reviews Immunology 10:2, 145-152
     

138. 138

     J. Smith-Palmer, B. H. Curtis, K. S. Boye, G. Goodall, S. R. Pillemer. (2010) Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis. Diabetic Medicine 27:2, 189-196
     

139. 139

     Clare A. Notley, Fiona E. McCann, Julia J. Inglis, Richard O. Williams. (2010) ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ treg cells and induces sustained amelioration of collagen-induced arthritis. Arthritis & Rheumatism 62:1, 171-178
     

140. 140

     Scott M. Steward-Tharp, Yun-jeong Song, Richard M. Siegel, John J. O'Shea. (2010) New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Annals of the New York Academy of Sciences 1183:1, 123-148
     

141. 141

     Yaron Ilan, Ehud Zigmond, Gadi Lalazar, Adi Dembinsky, Ami Ben Ya’acov, Nila Hemed, Ibrahim Kasis, Elizabeth Axelrod, Lidya Zolotarov, Athalia Klein, Madi Haj, Roopali Gandhi, Claire Baecher-Allan, Henry Wu, Gopal Murugaiyan, Pia Kivisakk, Mauricio F. Farez, Francisco J. Quintana, Samia J. Khoury, Howard L. Weiner. (2010) Oral Administration of OKT3 Monoclonal Antibody to Human Subjects Induces a Dose-Dependent Immunologic Effect in T Cells and Dendritic Cells. Journal of Clinical Immunology 30:1, 167-177
     

142. 142

     , E. Vandemeulebroucke, B. Keymeulen, K. Decochez, I. Weets, C. Block, F. Féry, U. Velde, I. Vermeulen, P. Pauw, C. Mathieu, D. G. Pipeleers, F. K. Gorus. (2010) Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia 53:1, 36-44
     

143. 143

     Physiopathologie des états diabétiques. In: Diabétologie. Elsevier, 2010:11-36.
     

144. 144

     Diane K. Wherrett, Denis Daneman. (2009) Prevention of Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America 38:4, 777-790
     

145. 145

     Pescovitz , Mark D. , Greenbaum , Carla J. , Krause-Steinrauf , Heidi , Becker , Dorothy J. , Gitelman , Stephen E. , Goland , Robin , Gottlieb , Peter A. , Marks , Jennifer B. , McGee , Paula F. , Moran , Antoinette M. , Raskin , Philip , Rodriguez , Henry , Schatz , Desmond A. , Wherrett , Diane , Wilson , Darrell M. , Lachin , John M. , Skyler , Jay S. , . (2009) Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. New England Journal of Medicine 361:22, 2143-2152
     Free Full Text

146. 146

     B. Peng, P. Ye, D. J. Rawlings, H. D. Ochs, C. H. Miao. (2009) Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Blood 114:20, 4373-4382
     

147. 147

     Michael D. McCall, Christian Toso, Emmanuel E. Baetge, A. M. James Shapiro. (2009) Are stem cells a cure for diabetes?. Clinical Science 118:2, 87-97
     

148. 148

     S. L. Thrower, P. J. Bingley. (2009) Strategies to prevent type 1 diabetes. Diabetes, Obesity and Metabolism 11:10, 931-938
     

149. 149

     Jennifer Sherr, Eda Cengiz, William V. Tamborlane. (2009) From pumps to prevention: recent advances in the treatment of type 1 diabetes. Drug Discovery Today 14:19-20, 973-981
     

150. 150

     Dong-Sheng Li, Garth L. Warnock, Han-Jun Tu, Ziliang Ao, Zehua He, Hong Lu, Long-Jun Dai. (2009) Do immunotherapy and ß cell replacement play a synergistic role in the treatment of type 1 diabetes?. Life Sciences 85:15-16, 549-556
     

151. 151

     George Vlad, Michael B. Stokes, Zhuoru Liu, Chih-Chao Chang, Hugo Sondermeijer, Elena R. Vasilescu, Adriana I. Colovai, Pasquale Berloco, Vivette D. D'Agati, Lloyd Ratner, Raffaello Cortesini, Nicole Suciu-Foca. (2009) Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc. Human Immunology 70:9, 663-669
     

152. 152

     E. Vandemeulebroucke, F.K. Gorus, K. Decochez, I. Weets, B. Keymeulen, C. De Block, J. Tits, D.G. Pipeleers, C. Mathieu. (2009) Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes & Metabolism 35:4, 319-327
     

153. 153

     Hideki Garren. (2009) DNA vaccines for autoimmune diseases. Expert Review of Vaccines 8:9, 1195-1203
     

154. 154

     Michael J. Haller, Mark A. Atkinson, Desmond A. Schatz. (2009) The road not taken: A path to curing type 1 diabetes?. European Journal of Immunology 39:8, 2054-2058
     

155. 155

     Matthias von Herrath, Gerald T. Nepom. (2009) Remodeling rodent models to mimic human type 1 diabetes. European Journal of Immunology 39:8, 2049-2054
     

156. 156

     Shawn Winer, Yin Chan, Geoffrey Paltser, Dorothy Truong, Hubert Tsui, Jasmine Bahrami, Ruslan Dorfman, Yongqian Wang, Julian Zielenski, Fabrizio Mastronardi, Yuko Maezawa, Daniel J Drucker, Edgar Engleman, Daniel Winer, H.-Michael Dosch. (2009) Normalization of obesity-associated insulin resistance through immunotherapy. Nature Medicine 15:8, 921-929
     

157. 157

     Kevan C. Herold, Stephen Gitelman, Carla Greenbaum, Jennifer Puck, William Hagopian, Peter Gottlieb, Peter Sayre, Peter Bianchine, Emelita Wong, Vicki Seyfert-Margolis, Kasia Bourcier, Jeffrey A. Bluestone. (2009) Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clinical Immunology 132:2, 166-173
     

158. 158

     Lucienne Chatenoud. (2009) Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Current Opinion in Organ Transplantation 14:4, 351-356
     

159. 159

     Creg J. Workman, Andrea L. Szymczak-Workman, Lauren W. Collison, Meenu R. Pillai, Dario A. A. Vignali. (2009) The development and function of regulatory T cells. Cellular and Molecular Life Sciences 66:16, 2603-2622
     

160. 160

     Andrew W. Norris, Joseph I. Wolfsdorf. Diabetes Mellitus. In: Brook's Clinical Pediatric Endocrinology. Wiley-Blackwell, 2009:458-504.
     

161. 161

     Nicole A. Belmar, John R. Lombardo, Debra T. Chao, Olga Li, Xiaohong Ma, Melody Pong-Afar, Debbie A. Law, Gary C. Starling. (2009) Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model. Journal of Neuroimmunology 212:1-2, 65-73
     

162. 162

     Shomyseh Sanjabi, Munir M. Mosaheb, Richard A. Flavell. (2009) Opposing Effects of TGF-β and IL-15 Cytokines Control the Number of Short-Lived Effector CD8+ T Cells. Immunity 31:1, 131-144
     

163. 163

     Michael A. Zimmerman, Sonia C. Flores. (2009) Autoimmune-Mediated Oxidative Stress and Endothelial Dysfunction: Implications of Accelerated Vascular Injury in Type I Diabetes. Journal of Surgical Research 155:1, 173-178
     

164. 164

     Alberto Falorni, Annalisa Brozzetti, Filippo Calcinaro, Stefania Marzotti, Fausto Santeusanio. (2009) Recent advances in adrenal autoimmunity. Expert Review of Endocrinology & Metabolism 4:4, 333-348
     

165. 165

     Frank Waldron-Lynch, Kevan C. Herold. (2009) Advances in Type 1 Diabetes Therapeutics: Immunomodulation and β-Cell Salvage. Endocrinology and Metabolism Clinics of North America 38:2, 303-317
     

166. 166

     Adam Kaufman, Kevan C. Herold. (2009) Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes/Metabolism Research and Reviews 25:4, 302-306
     

167. 167

     Paolo Pozzilli, R. David Leslie. (2009) New prospects for immunotherapy at diagnosis of type 1 diabetes. Diabetes/Metabolism Research and Reviews 25:4, 299-301
     

168. 168

     A. W. Michels, G. S. Eisenbarth. (2009) Autoimmune polyendocrine syndrome type 1 (APS-1) as a model for understanding autoimmune polyendocrine syndrome type 2 (APS-2). Journal of Internal Medicine 265:5, 530-540
     

169. 169

     Jerry P. Palmer. (2009) C-peptide in the natural history of type 1 diabetes. Diabetes/Metabolism Research and Reviews 25:4, 325-328
     

170. 170

     E. Jaeckel, F. Lehner. (2009) Pankreas- und Inseltransplantation. Der Internist 50:5, 536-549
     

171. 171

     Concannon , Patrick , Rich , Stephen S. , Nepom , Gerald T. , . (2009) Genetics of Type 1A Diabetes. New England Journal of Medicine 360:16, 1646-1654
     Full Text

172. 172

     Makoto Miyara, Kajsa Wing, Shimon Sakaguchi. (2009) Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. Journal of Allergy and Clinical Immunology 123:4, 749-755
     

173. 173

     Yasmine Belkaid, Kristin Tarbell. (2009) Regulatory T Cells in the Control of Host-Microorganism Interactions ^*. Annual Review of Immunology 27:1, 551-589
     

174. 174

     Sylvaine You. (2009) CD3-specific antibodies to restore tolerance in autoimmune diabetes. Drug Discovery Today: Therapeutic Strategies 6:1, 33-38
     

175. 175

     M. Reimann, E. Bonifacio, M. Solimena, P.E.H. Schwarz, B. Ludwig, M. Hanefeld, S.R. Bornstein. (2009) An update on preventive and regenerative therapies in diabetes mellitus. Pharmacology & Therapeutics 121:3, 317-331
     

176. 176

     Jeffrey L Mahon, Jay M Sosenko, Lisa Rafkin-Mervis, Heidi Krause-Steinrauf, John M Lachin, Clinton Thompson, Polly J Bingley, Ezio Bonifacio, Jerry P Palmer, George S Eisenbarth, Joseph Wolfsdorf, Jay S Skyler, , . (2009) The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatric Diabetes 10:2, 97-104
     

177. 177

     S. L. Thrower, L. James, W. Hall, K. M. Green, S. Arif, J. S. Allen, C. Van-Krinks, B. Lozanoska-Ochser, L. Marquesini, S. Brown, F. S. Wong, C. M. Dayan, M. Peakman. (2009) Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clinical & Experimental Immunology 155:2, 156-165
     

178. 178

     B. Waters, M. Qadura, E. Burnett, R. Chegeni, A. Labelle, P. Thompson, C. Hough, D. Lillicrap. (2009) Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood 113:1, 193-203
     

179. 179

     Myung-Shik Lee, Kyoung-Ah Kim. (2009) Type 1 Diabetes Mellitus. Journal of the Korean Medical Association 52:7, 677
     

180. 180

     J. M. Lawson, J. Tremble, C. Dayan, H. Beyan, R. D. G. Leslie, M. Peakman, T. I. M. Tree. (2008) Increased resistance to CD4 ⁺ CD25 ^hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clinical & Experimental Immunology 154:3, 353-359
     

181. 181

     Jeffrey A. Bluestone, Qizhi Tang, Caitlin E. Sedwick. (2008) T Regulatory Cells in Autoimmune Diabetes: Past Challenges, Future Prospects. Journal of Clinical Immunology 28:6, 677-684
     

182. 182

     Eliana Mariño, Shane T. Grey. (2008) A new role for an old player: Do B cells unleash the self-reactive CD8+ T cell storm necessary for the development of type 1 diabetes?. Journal of Autoimmunity 31:3, 301-305
     

183. 183

     Vitaly Ablamunits, Kevan C. Herold. (2008) Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3γ1(Ala-Ala). Human Immunology 69:11, 732-736
     

184. 184

     Hirofumi Ochi, Michal Abraham, Hiroki Ishikawa, Dan Frenkel, Kaiyong Yang, Alexandre Basso, Henry Wu, Mei-Ling Chen, Roopali Gandhi, Ariel Miller, Ruth Maron, Howard L. Weiner. (2008) New immunosuppressive approaches: Oral administration of CD3-specific antibody to treat autoimmunity. Journal of the Neurological Sciences 274:1-2, 9-12
     

185. 185

     Lucy SK Walker. (2008) Natural Treg in autoimmune diabetes: all present and correct?. Expert Opinion on Biological Therapy 8:11, 1691-1703
     

186. 186

     M. Koulmanda, M. Bhasin, L. Hoffman, Z. Fan, A. Qipo, H. Shi, S. Bonner-Weir, P. Putheti, N. Degauque, T. A. Libermann, H. Auchincloss, J. S. Flier, T. B. Strom. (2008) Curative and   cell regenerative effects of  1-antitrypsin treatment in autoimmune diabetic NOD mice. Proceedings of the National Academy of Sciences 105:42, 16242-16247
     

187. 187

     Bo Wang, Roland Tisch. (2008) Parameters influencing antigen-specific immunotherapy for Type 1 diabetes. Immunologic Research 42:1-3, 246-258
     

188. 188

     F. Susan Wong, Colin M. Dayan. (2008) Regulatory T cells in autoimmune endocrine diseases. Trends in Endocrinology & Metabolism 19:8, 292-299
     

189. 189

     J. D. Isaacs. (2008) Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology 47:10, 1461-1468
     

190. 190

     Jennifer Bollyky, Srinath Sanda, Carla J. Greenbaum. (2008) Type 1 diabetes mellitus: primary, secondary, and tertiary prevention. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 75:4, 385-397
     

191. 191

     Bo Wang, Roland Tisch. (2008) Parameters influencing antigen-specific immunotherapy for type 1 diabetes. Immunologic Research 41:3, 175-187
     

192. 192

     V. A. L. Huurman, P. E. Van Der Meide, G. Duinkerken, S. Willemen, I. R. Cohen, D. Elias, B. O. Roep. (2008) Immunological efficacy of heat shock protein 60 peptide DiaPep277TM therapy in clinical type I diabetes. Clinical & Experimental Immunology 152:3, 488-497
     

193. 193

     Nick Giannoukakis, Brett Phillips, Massimo Trucco. (2008) Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond. Pediatric Diabetes 9:3pt2, 4-13
     

194. 194

     Irene Jarchum, Lynn Nichol, Massimo Trucco, Pere Santamaria, Teresa P. DiLorenzo. (2008) Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clinical Immunology 127:3, 359-365
     

195. 195

     Qi T. Yu, Masayuki Saruta, Konstantinos A. Papadakis. (2008) Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clinical Immunology 127:3, 322-329
     

196. 196

     Srinath Sanda, Bart O. Roep, Matthias von Herrath. (2008) Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clinical Immunology 127:2, 138-143
     

197. 197

     Stanley R. Pillemer. (2008) Preserving β Cells in Type 1 Diabetes mellitus: the role of immunological tolerance. Drug Development Research 69:3, 153-157
     

198. 198

     J. J. Meier. (2008) Beta cell mass in diabetes: a realistic therapeutic target?. Diabetologia 51:5, 703-713
     

199. 199

     Marc Rendell. (2008) Insulin: moments in history. Drug Development Research 69:3, 95-100
     

200. 200

     Jennifer Sherr, Jay Sosenko, Jay S Skyler, Kevan C Herold. (2008) Prevention of type 1 diabetes: the time has come. Nature Clinical Practice Endocrinology & Metabolism
     

201. 201

     Huanfa Yi, Jialin Zhang, Yong Zhao. (2008) The effects of antibody treatment on regulatory CD4+CD25+ T cells. Transplant Immunology 19:1, 37-44
     

202. 202

     Guojiang Chen, Gencheng Han, Jianan Wang, Renxi Wang, Ruonan Xu, Beifen Shen, Jiahua Qian, Yan Li. (2008) Induction of Active Tolerance and Involvement of CD1d-Restricted Natural Killer T Cells in Anti-CD3 F(ab′)2 Treatment-Reversed New-Onset Diabetes in Nonobese Diabetic Mice. The American Journal of Pathology 172:4, 972-979
     

203. 203

     Tyler R. Hall, Marika Bogdani, Renee C. LeBoeuf, Elizabeth A. Kirk, Marlena Maziarz, J. Paul Banga, Shilpa Oak, Christina A. Pennington, Christiane S. Hampe. (2008) Modulation of diabetes in NOD mice by GAD65-specific monoclonal antibodies is epitope specific and accompanied by anti-idiotypic antibodies. Immunology 123:4, 547-554
     

204. 204

     Peter Achenbach, Jennifer Barker, Ezio Bonifacio. (2008) Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Current Diabetes Reports 8:2, 87-93
     

205. 205

     Howard L. Weiner. (2008) A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. Journal of Neurology 255:S1, 3-11
     

206. 206

     Harvey Chiu, Catherine Pihoker. Treatment Patterns in Youth with Diabetes. In: Epidemiology of Pediatric and Adolescent Diabetes. CRC Press, 2008:303-322.
     

207. 207

     Craig Taplin, Jennifer Barker. Natural Evolution, Prediction and Prevention of Type 1 Diabetes in Youth. In: Epidemiology of Pediatric and Adolescent Diabetes. CRC Press, 2008:185-199.
     

208. 208

     Michal Abraham, Arnon Karni, Adi Dembinsky, Ariel Miller, Roopali Gandhi, David Anderson, Howard L. Weiner. (2008) In vitro induction of regulatory T cells by anti-CD3 antibody in humans. Journal of Autoimmunity 30:1-2, 21-28
     

209. 209

     M. Chianelli, M. G. Parisella, N. Visalli, S. J. Mather, C. D'Alessandria, P. Pozzilli, A. Signore, . (2008) Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. Diabetes/Metabolism Research and Reviews 24:2, 115-122
     

210. 210

     Mohammed Javeed I. Ansari, Paolo Fiorina, Shirine Dada, Indira Guleria, Takuya Ueno, Xueli Yuan, Subbulaxmi Trikudanathan, R. Neal Smith, Gordon Freeman, Mohamed H. Sayegh. (2008) Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clinical Immunology 126:2, 140-147
     

211. 211

     Ping-Ying Pan, Junko Ozao, Zuping Zhou, Shu-Hsia Chen. (2008) Advancements in immune tolerance. Advanced Drug Delivery Reviews 60:2, 91-105
     

212. 212

     Castle J. Funatake, Nikki B. Marshall, Nancy I. Kerkvliet. (2008) 2,3,7,8-Tetrachlorodibenzo- p -dioxin Alters the Differentiation of Alloreactive CD8 ⁺ T Cells Toward a Regulatory T Cell Phenotype by a Mechanism that is Dependent on Aryl Hydrocarbon Receptor in CD4 ⁺ T Cells. Journal of Immunotoxicology 5:1, 81-91
     

213. 213

     Veronika S. Urbán, Judit Kiss, János Kovács, Elen Gócza, Virág Vas, Ėva Monostori, Ferenc Uher. (2008) Mesenchymal Stem Cells Cooperate with Bone Marrow Cells in Therapy of Diabetes. Stem Cells 26:1, 244-253
     

214. 214

     Allan D. Kirk. Antibodies and Fusion Proteins. In: Kidney Transplantation. Elsevier, 2008:309-332.
     

215. 215

     MARK A. SPERLING, STUART A. WEINZIMER, WILLIAM V. TAMBORLANE. Diabetes Mellitus. In: Pediatric Endocrinology. Elsevier, 2008:374-421.
     

216. 216

     Lorenzo Pasquali, Nick Giannoukakis, Massimo Trucco. (2008) Induction of immune tolerance to facilitate β cell regeneration in type 1 diabetes. Advanced Drug Delivery Reviews 60:2, 106-113
     

217. 217

     George S. Eisenbarth. Diabetes and related autoimmune diseases. In: Clinical Immunology. Elsevier, 2008:1035-1052.
     

218. 218

     Carlos Eduardo Barra Couri, Maria Cristina Foss-Freitas, Milton César Foss, Júlio César Voltarelli. (2008) β-cell regeneration to treat Type 1 diabetes mellitus. Expert Review of Endocrinology & Metabolism 3:1, 51-60
     

219. 219

     Sylvaine You, Sophie Candon, Chantal Kuhn, Jean-François Bach, Lucienne Chatenoud. Chapter 2 CD3 Antibodies as Unique Tools to Restore Self-Tolerance in Established Autoimmunity. Elsevier, 2008:13-37.
     

220. 220

     Hugh O. McDevitt, Emil R. Unanue. Chapter 1 Autoimmune Diabetes Mellitus—Much Progress, but Many Challenges. Elsevier, 2008:1-12.
     

221. 221

     Jennifer M. Barker. Chapter 5 The Pathogenesis of Type 1 Diabetes. Elsevier, 2008:45-59.
     

222. 222

     R Naik, J Palmer. Latent Autoimmune Diabetes in Adults. In: Type 1 Diabetes in Adults. CRC Press, 2007:17-32.
     

223. 223

     Peter C Butler, Juris J Meier, Alexandra E Butler, Anil Bhushan. (2007) The replication of β cells in normal physiology, in disease and for therapy. Nature Clinical Practice Endocrinology & Metabolism 3:11, 758-768
     

224. 224

     M. C. Ruzek, J. S. Waire, D. Hopkins, G. LaCorcia, J. Sullivan, B. L. Roberts, S. M. Richards, S. R. Nahill, J. M. Williams, A. Scaria, J. Dzuris, S. Shankara, R. D. Garman. (2007) Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo. Blood 111:3, 1726-1734
     

225. 225

     Ping Lü, Fang Liu, Lei Yan, Tao Peng, Tao Liu, Zhong Yao, Chun-You Wang. (2007) Stem cells therapy for type 1 diabetes. Diabetes Research and Clinical Practice 78:1, 1-7
     

226. 226

     Tomer Nir, Douglas A. Melton, Yuval Dor. (2007) Recovery from diabetes in mice by β cell regeneration. Journal of Clinical Investigation 117:9, 2553-2561
     

227. 227

     Stephen D. Miller, Danielle M. Turley, Joseph R. Podojil. (2007) Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nature Reviews Immunology 7:9, 665-677
     

228. 228

     Georgia Fousteri, Alberto Hayek, Matthias von Herrath. (2007) Stopping diabetes in its tracks: autologous non-myeloablative stem cell transplantation. Regenerative Medicine 2:5, 845-851
     

229. 229

     I. Truyen, J. De Grijse, I. Weets, L. Kaufman, L. Pipeleers, N. Nanos, K. Decochez, R. Hilbrands, J-M. Kaufman, B. Keymeulen, C. Mathieu, L. Van Gaal, D. G. Pipeleers, F. K. Gorus, . (2007) Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes. Clinical & Experimental Immunology 149:2, 243-250
     

230. 230

     D. T. Chung, T. Korn, J. Richard, M. Ruzek, A. P. Kohm, S. Miller, S. Nahill, M. Oukka. (2007) Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells. International Immunology 19:8, 1003-1010
     

231. 231

     Lucienne Chatenoud, Jeffrey A. Bluestone. (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nature Reviews Immunology 7:8, 622-632
     

232. 232

     Alex Rabinovitch, Wilma L. Suarez-Pinzon. (2007) Roles of cytokines in the pathogenesis and therapy of type 1 diabetes. Cell Biochemistry and Biophysics 48:2-3, 159-163
     

233. 233

     P. Van De Linde, P. J. M. vd Boog, O. M. H. Tysma, J. F. Elliott, D. L. Roelen, F. H. J. Claas, J. W. De Fijter, B. O. Roep. (2007) Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin. Clinical & Experimental Immunology 149:1, 56-62
     

234. 234

     James W Verbsky. (2007) Therapeutic use of T regulatory cells. Current Opinion in Rheumatology 19:3, 252-258
     

235. 235

     Volkert A. L. Huurman, Katelijn Decochez, Chantal Mathieu, Irun R. Cohen, Bart O. Roep. (2007) Therapy with the hsp60 peptide DiaPep277™ in C-peptide positive type 1 diabetes patients. Diabetes/Metabolism Research and Reviews 23:4, 269-275
     

236. 236

     L. Lazar, R. Ofan, N. Weintrob, A. Avron, M. Tamir, D. Elias, M. Phillip, Z. Josefsberg. (2007) Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes/Metabolism Research and Reviews 23:4, 286-291
     

237. 237

     Nanette C. Schloot, Guido Meierhoff, Csaba Lengyel, Gyözö Vándorfi, József Takács, Pál Pánczél, László Barkai, László Madácsy, Tamás Oroszlán, Peter Kovács, Gábor Sütö, Tadej Battelino, Nora Hosszufalusi, György Jermendy. (2007) Effect of heat shock protein peptide DiaPep277 on ß-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes/Metabolism Research and Reviews 23:4, 276-285
     

238. 238

     J S Skyler. (2007) Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects. Clinical Pharmacology & Therapeutics 81:5, 768-771
     

239. 239

     B. Sawitzki, A. Bushell, U. Steger, N. Jones, K. Risch, A. Siepert, M. Lehmann, I. Schmitt-Knosalla, K. Vogt, I. Gebuhr, K. Wood, H.-D. Volk. (2007) Identification of Gene Markers for the Prediction of Allograft Rejection or Permanent Acceptance. American Journal of Transplantation 7:5, 1091-1102
     

240. 240

     S. You, B. Leforban, C. Garcia, J.-F. Bach, J. A. Bluestone, L. Chatenoud. (2007) Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proceedings of the National Academy of Sciences 104:15, 6335-6340
     

241. 241

     T. Staeva-Vieira, M. Peakman, M. Von Herrath. (2007) Translational Mini-Review Series on Type 1 Diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clinical & Experimental Immunology 148:1, 17-31
     

242. 242

     Tanuja Chitnis, Samia Khoury. T cell-based therapies in multiple sclerosis. In: Multiple Sclerosis Therapeutics, Third Edition. CRC Press, 2007:595-611.
     

243. 243

     C. Baker, L. Chang, K. A. Elsegood, A. J. Bishop, D. H. Gannon, P. Narendran, N. J. Leech, C. M. Dayan. (2007) Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR ⁺  CD30 ⁺ subpopulation in new-onset disease. Clinical & Experimental Immunology 147:3, 472-482
     

244. 244

     Christophe M Filippi, Matthias G von Herrath. (2007) Strategies to treat autoimmune diabetes. Expert Review of Endocrinology & Metabolism 2:2, 185-194
     

245. 245

     E. William St. Clair, Larry A. Turka, Andrew Saxon, Jeffrey B. Matthews, Mohamed H. Sayegh, George S. Eisenbarth, Jeffrey Bluestone. (2007) New Reagents on the Horizon for Immune Tolerance. Annual Review of Medicine 58:1, 329-346
     

246. 246

     Christopher M. Kishiyama, H. Peter Chase, Jennifer M. Barker. (2007) Prevention strategies for type 1 diabetes. Reviews in Endocrine and Metabolic Disorders 7:3, 215-224
     

247. 247

     Modesta P. Ndejembi, Anita L. Tang, Donna L. Farber. (2007) Reshaping the past: Strategies for modulating T-cell memory immune responses. Clinical Immunology 122:1, 1-12
     

248. 248

     Arno Hänninen, Rita Nurmela, Mikael Maksimow, Jarkko Heino, Sirpa Jalkanen, Christian Kurts. (2007) Islet β-Cell-Specific T Cells Can Use Different Homing Mechanisms to Infiltrate and Destroy Pancreatic Islets. The American Journal of Pathology 170:1, 240-250
     

249. 249

     Vibeke Strand, Robert Kimberly, John D. Isaacs. (2007) Biologic therapies in rheumatology: lessons learned, future directions. Nature Reviews Drug Discovery 6:1, 75-92
     

250. 250

     Eric H Liu, Richard M Siegel, David M Harlan, John J O'Shea. (2007) T cell–directed therapies: lessons learned and future prospects. Nature Immunology 8:1, 25-30
     

251. 251

     Ming Lv, Yan Li, Ming Yu, Yingxun Sun, Zhou Lin, Chunxia Qiao, Qun Luo, Xin Gu, Ying Huang, Jiannan Feng, Beifen Shen. (2007) Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design. The International Journal of Biochemistry & Cell Biology 39:6, 1142-1155
     

252. 252

     Antonella Maffei, Paul E Harris. (2007) Targeting vesicular monoamine transporter Type 2 for noninvasive PET-based β-cell mass measurements. Expert Review of Endocrinology & Metabolism 2:1, 35-46
     

253. 253

     John Dupre, L. Jeffrey, Mahon. (2007) Preventive Interventions for Type 1 Diabetes: History, Appraisal and Prospects. Canadian Journal of Diabetes 31:4, 384-394
     

254. 254

     Lucienne Chatenoud. (2006) Immune therapies of autoimmune diseases: are we approaching a real cure?. Current Opinion in Immunology 18:6, 710-717
     

255. 255

     Hans J.P.M. Koenen, Irma Joosten. (2006) Antigen-Specific Regulatory T-Cell Subsets in Transplantation Tolerance. Human Immunology 67:9, 665-675
     

256. 256

     Ingo H Tarner, C Garrison Fathman. (2006) Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease?. Nature Clinical Practice Rheumatology 2:9, 491-499
     

257. 257

     B. Z. Alizadeh, P. Hanifi-Moghaddam, P. Eerligh, A. R. van der Slik, H. Kolb, A. V. Kharagjitsingh, A. M. Pereira Arias, M. Ronkainen, M. Knip, R. Bonfanti, E. Bonifacio, D. Devendra, T. Wilkin, M. J. Giphart, B. P. C. Koeleman, R. Nolsoe, T. Mandrup Poulsen, N. C. Schloot, B. O. Roep. (2006) Association of interferon-γ and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes. Clinical and Experimental Immunology 145:3, 480-484
     

258. 258

     Mark Peakman, Bart O Roep. (2006) Secondary measures of immunologic efficacy in clinical trials. Current Opinion in Endocrinology and Diabetes 13:4, 325-331
     

259. 259

     Dawn M Gross, Karen E Earle, Jeffrey A Bluestone, Qizhi Tang. (2006) Regulatory T cells and their role in type 1 diabetes. Current Opinion in Endocrinology and Diabetes 13:4, 319-324
     

260. 260

     Sylvaine You, Nathalie Thieblemont, Marie‐Alexandra Alyanakian, Jean‐Francois Bach, Lucienne Chatenoud. (2006) Transforming growth factor‐β and T‐cell‐mediated immunoregulation in the control of autoimmune diabetes. Immunological Reviews 212:1, 185-202
     

261. 261

     Maria Grazia Roncarolo, Silvia Gregori, Manuela Battaglia, Rosa Bacchetta, Katharina Fleischhauer, Megan K. Levings. (2006) Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews 212:1, 28-50
     

262. 262

     Qizhi Tang, Jeffrey A. Bluestone. (2006) Regulatory T-cell physiology and application to treat autoimmunity.. Immunological Reviews 212:1, 217-237
     

263. 263

     Richard Burt, Larissa Verda, I de Kleer, Nico Wulffraat. Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases in Children. In: Pediatric Hematopoietic Stem Cell Transplantation. CRC Press, 2006:449-476.
     

264. 264

     Melton , Douglas A. , . (2006) Reversal of Type 1 Diabetes in Mice. New England Journal of Medicine 355:1, 89-90
     Full Text

265. 265

     Hirofumi Ochi, Michal Abraham, Hiroki Ishikawa, Dan Frenkel, Kaiyong Yang, Alexandre S Basso, Henry Wu, Mei-Ling Chen, Roopali Gandhi, Ariel Miller, Ruth Maron, Howard L Weiner. (2006) Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells. Nature Medicine 12:6, 627-635
     

266. 266

     Alice Li, Okechukwu Ojogho, Edson Franco, Pedro Baron, Yuichi Iwaki, Alan Escher. (2006) Pro-apoptotic DNA vaccination ameliorates new onset of autoimmune diabetes in NOD mice and induces foxp3+ regulatory T cells in vitro. Vaccine 24:23, 5036-5046
     

267. 267

     Lucienne Chatenoud. (2006) Weaned from the needle. Nature Medicine 12:6, 617-618
     

268. 268

     Jian Li, Janet Davis, Michelle Bracht, Jill Carton, Jennifer Armstrong, Wei Gao, Bernie Scallon, Ramie Fung, Eva Emmell, Mark Zimmerman, Don E. Griswold, Li Li. (2006) Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody. International Immunopharmacology 6:6, 880-891
     

269. 269

     Margrit Wiesendanger, Anfisa Stanevsky, Susan Kovsky, Betty Diamond. (2006) Novel therapeutics for systemic lupus erythematosus. Current Opinion in Rheumatology 18:3, 227-235
     

270. 270

     Alberto Pugliese. (2006) Insulin: a critical autoantigen and potential therapeutic agent in Type 1 diabetes. Expert Review of Clinical Immunology 2:3, 419-431
     

271. 271

     Angela Bauch, Giulio Superti-Furga. (2006) Charting protein complexes, signaling pathways, and networks in the immune system. Immunological Reviews 210:1, 187-207
     

272. 272

     Martin A. Kriegel, Ming O. Li, Shomyseh Sanjabi, Yisong Y. Wan, Richard A. Flavell. (2006) Transforming growth factor-β: Recent advances on its role in immune tolerance. Current Rheumatology Reports 8:2, 138-144
     

273. 273

     Ming O. Li, Yisong Y. Wan, Shomyseh Sanjabi, Anna-Karin L. Robertson, Richard A. Flavell. (2006) TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES. Annual Review of Immunology 24:1, 99-146
     

274. 274

     Michael H Albert, Claudio Anasetti, Xue-Zhong Yu. (2006) T regulatory cells as an immunotherapy for transplantation. Expert Opinion on Biological Therapy 6:4, 315-324
     

275. 275

     Sylvain Fisson, Fathia Djelti, Aurélie Trenado, Fabienne Billiard, Roland Liblau, David Klatzmann, José L. Cohen, Benoît L. Salomon. (2006) Therapeutic potential of self-antigen-specific CD4+CD25+ regulatory T cells selectedin vitro from a polyclonal repertoire. European Journal of Immunology 36:4, 817-827
     

276. 276

     P. van de Linde, O.M.H. Tysma, J.P. Medema, G. Hale, H. Waldmann, D.L. Roelen, B.O. Roep. (2006) Mechanisms of Antibody Immunotherapy on Clonal Islet Reactive T Cells. Human Immunology 67:4-5, 264-273
     

277. 277

     Christian Dejaco, Christina Duftner, Beatrix Grubeck-Loebenstein, Michael Schirmer. (2006) Imbalance of regulatory T cells in human autoimmune diseases. Immunology 117:3, 289-300
     

278. 278

     Carla J. Greenbaum. (2006) Progress, but not yet ready for clinical use: Interrupting immune-mediated destruction of pancreatic β cells in type 1 diabetes. Current Diabetes Reports 6:2, 93-95
     

279. 279

     Ming O Li, Richard A Flavell. (2006) TGF-β, T-cell tolerance and immunotherapy of autoimmune diseases and cancer. Expert Review of Clinical Immunology 2:2, 257-265
     

280. 280

     Simona Cernea, Kevan C Herold. (2006) Drug Insight: new immunomodulatory therapies in type 1 diabetes. Nature Clinical Practice Endocrinology & Metabolism 2:2, 89-98
     

281. 281

     David A. Randolph, C. Garrison Fathman. (2006) CD4 ⁺ CD25 ⁺ Regulatory T Cells and Their Therapeutic Potential. Annual Review of Medicine 57:1, 381-402
     

282. 282

     P. Hanifi-Moghaddam, S. Kappler, J. Seissler, S. Muller-Scholze, S. Martin, B. O. Roep, K. Strassburger, H. Kolb, N. C. Schloot. (2006) Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus. Diabetic Medicine 23:2, 156-163
     

283. 283

     , E. B. Tsai, N. A. Sherry, J. P. Palmer, K. C. Herold. (2006) The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 49:2, 261-270
     

284. 284

     Lucienne Chatenoud. (2006) CD3-Specific Antibodies as Promising Tools to Aim at Immune Tolerance in the Clinic. International Reviews of Immunology 25:3-4, 215-233
     

285. 285

     Wayne Truong, A M James Shapiro. (2006) Progress in Islet Transplantation in Patients with Type 1 Diabetes Mellitus. Treatments in Endocrinology 5:3, 147-158
     

286. 286

     Sulaiman A. Nanji, A. M. James Shapiro. (2006) Advances in pancreatic islet transplantation in humans. Diabetes, Obesity and Metabolism 8:1, 15-25
     

287. 287

     Shinichi Matsumoto, Hirofumi Noguchi, Yukihide Yonekawa, Teru Okitsu, Yasuhiro Iwanaga, Xiaoling Liu, Hideo Nagata, Naoya Kobayashi, Camillo Ricordi. (2006) Pancreatic islet transplantation for treating diabetes. Expert Opinion on Biological Therapy 6:1, 23-37
     

288. 288

     Stephen W. Martin, Martin F. Bachmann. Vaccination to treat noninfectious diseases. In: Immunopotentiators in Modern Vaccines. Elsevier, 2006:289-317.
     

289. 289

     Leonard C. Harrison. Prevention of Autoimmune Disease. In: The Autoimmune Diseases. Elsevier, 2006:1045-1062.
     

290. 290

     Lucienne Chatenoud. Emerging Therapies for Autoimmune Diseases. In: The Autoimmune Diseases. Elsevier, 2006:1063-1081.
     

291. 291

     Jean-François Bach. Type 1 Diabetes. In: The Autoimmune Diseases. Elsevier, 2006:483-500.
     

292. 292

     Lucienne Chatenoud. (2005) CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Current Opinion in Immunology 17:6, 632-637
     

293. 293

     Anna Casu, Massimo Trucco, Massimo Pietropaolo. (2005) A Look to the Future: Prediction, Prevention, and Cure Including Islet Transplantation and Stem Cell Therapy. Pediatric Clinics of North America 52:6, 1779-1804
     

294. 294

     Roberto Mallone, Gerald T Nepom. (2005) Targeting T Lymphocytes for Immune Monitoring and Intervention in Autoimmune Diabetes. American Journal of Therapeutics 12:6, 534-550
     

295. 295

     Pieter van de Linde, Bart O Roep. (2005) T-Cell Assays to Determine Disease Activity and Clinical Efficacy of Immune Therapy in Type 1 Diabetes. American Journal of Therapeutics 12:6, 573-579
     

296. 296

     Åke Lernmark, Carl-David Agardh. (2005) Immunomodulation with human recombinant autoantigens. Trends in Immunology 26:11, 608-612
     

297. 297

     OLE DRAGSBAEK MADSEN. (2005) Stem cells and diabetes treatment. APMIS 113:11-12, 858-875
     

298. 298

     Theresa Aly, Devasenan Devendra, George S Eisenbarth. (2005) Immunotherapeutic Approaches to Prevent, Ameliorate, and Cure Type 1 Diabetes. American Journal of Therapeutics 12:6, 481-490
     

299. 299

     Brygida Bisikirska, John Colgan, Jeremy Luban, Jeffrey A. Bluestone, Kevan C. Herold. (2005) TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. Journal of Clinical Investigation 115:10, 2904-2913
     

300. 300

     S. P. Cobbold. (2005) T cell tolerance induced by therapeutic antibodies. Philosophical Transactions of the Royal Society B: Biological Sciences 360:1461, 1695-1705
     

301. 301

     K Loser, W Hansen, J Apelt, S Balkow, J Buer, S Beissert. (2005) In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Therapy 12:17, 1294-1304
     

302. 302

     Lucienne Chatenoud, Jean-François Bach. (2005) Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance. Expert Opinion on Biological Therapy 5:s1, S73-S81
     

303. 303

     Lisl K.M. Shoda, Daniel L. Young, Saroja Ramanujan, Chan C. Whiting, Mark A. Atkinson, Jeffrey A. Bluestone, George S. Eisenbarth, Diane Mathis, Aldo A. Rossini, Scott E. Campbell, Richard Kahn, Huub T.C. Kreuwel. (2005) A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation. Immunity 23:2, 115-126
     

304. 304

     I. Conget, E. Aguilera, S. Pellitero, S. Näf, K. Bendtzen, R. Casamitjana, R. Gomis, F. Nicoletti. (2005) Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial. Diabetologia 48:8, 1464-1468
     

305. 305

     Erik Thorsby, Benedicte A. Lie. (2005) HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transplant Immunology 14:3-4, 175-182
     

306. 306

     David M Harlan, Matthias von Herrath. (2005) Immune intervention with anti-CD3 in diabetes. Nature Medicine 11:7, 716-718
     

307. 307

     Keymeulen , Bart , Vandemeulebroucke , Evy , Ziegler , Anette G. , Mathieu , Chantal , Kaufman , Leonard , Hale , Geoff , Gorus , Frans , Goldman , Michel , Walter , Markus , Candon , Sophie , Schandene , Liliane , Crenier , Laurent , De Block , Christophe , Seigneurin , Jean-Marie , De Pauw , Pieter , Pierard , Denis , Weets , Ilse , Rebello , Peppy , Bird , Pru , Berrie , Eleanor , Frewin , Mark Waldmann , Herman , Bach , Jean-François , Pipeleers , Daniel , Chatenoud , Lucienne , . (2005) Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes. New England Journal of Medicine 352:25, 2598-2608
     Free Full Text

308. 308

     Lernmark , Åke , . (2005) Type 1 Diabetes — Does Suppressing T Cells Increase Insulin?. New England Journal of Medicine 352:25, 2642-2644
     Full Text

309. 309

     Marc Feldmann, Lawrence Steinman. (2005) Design of effective immunotherapy for human autoimmunity. Nature 435:7042, 612-619
     

310. 310

     NARU BABAYA, MAKI NAKAYAMA, GEORGE S. EISENBARTH. (2005) The Stages of Type 1A Diabetes. Annals of the New York Academy of Sciences 1051:1, 194-204
     

311. 311

     Michael Lahn, Susanne Kloeker, Brandi S Berry. (2005) TGF-β inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs 14:6, 629-643
     

312. 312

     P. Pozzilli, S. Manfrini, R. Buzzetti, E. Lampeter, I.De. Leeuw, D. Iafusco, M. Prisco, C. Ionescu-Tirgoviste, S. Kolouskovà, T. Linn, J. Ludvigsson, L. Madàcsy, A.Seremak. Mrozikiewicz, P.M. Mrozikiewicz, T. Podar, J. Vavrinec, B. Vialettes, N. Visalli, T. Yilmaz, P.D. Browne. (2005) Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study. Diabetes Research and Clinical Practice 68:3, 258-264
     

313. 313

     A M. James Shapiro, Jonathan R.T. Lakey, Breay W. Paty, Peter A. Senior, David L. Bigam, Edmond A. Ryan. (2005) Strategic Opportunities in Clinical Islet Transplantation. Transplantation 79:10, 1304-1307
     

314. 314

     Takashi Maki, Rita Gottschalk, Norihiko Ogawa, Anthony P. Monaco. (2005) Prevention and Cure of Autoimmune Diabetes in Nonobese Diabetic Mice by Continuous Administration of FTY720. Transplantation 79:9, 1051-1055
     

315. 315

     Takanori Kanai, Mamoru Watanabe. (2005) Clinical application of human CD4 ⁺ CD25 ⁺ regulatory Tcells for the treatment of inflammatory bowel diseases. Expert Opinion on Biological Therapy 5:4, 451-462
     

316. 316

     Roberto Gianani, George S. Eisenbarth. (2005) The stages of type 1A diabetes: 2005. Immunological Reviews 204:1, 232-249
     

317. 317

     Mark S. Anderson, Jeffrey A. Bluestone. (2005) THE NOD MOUSE: A Model of Immune Dysregulation. Annual Review of Immunology 23:1, 447-485
     

318. 318

     Willem van Eden, Ruurd van der Zee, Berent Prakken. (2005) Heat-shock proteins induce T-cell regulation of chronic inflammation. Nature Reviews Immunology 5:4, 318-330
     

319. 319

     Itamar Raz, Roy Eldor, Yaakov Naparstek. (2005) Immune modulation for prevention of type 1 diabetes mellitus. Trends in Biotechnology 23:3, 128-134
     

320. 320

     Karine Hadaya, Hassen Kared, Annie Masson, Lucienne Chatenoud, Flora Zavala. (2005) G-CSF treatment prevents cyclophosphamide acceleration of autoimmune diabetes in the NOD mouse. Journal of Autoimmunity 24:2, 125-134
     

321. 321

     Massimo Trucco. (2005) Regeneration of the pancreatic β cell. Journal of Clinical Investigation 115:1, 5-12
     

322. 322

     Massimo Trucco. (2005) Regeneration of the pancreatic β cell. Journal of Clinical Investigation 115:1, 5-12
     

323. 323

     Lucienne Chatenoud, Jean-François Bach. (2005) Regulatory T Cells in the Control of Autoimmune Diabetes: The Case of the NOD Mouse. International Reviews of Immunology 24:3-4, 247-267
     

324. 324

     Adam P. Kohm, Danielle M. Turley, Stephen D. Miller. (2005) Targeting the TCR: T-Cell Receptor and Peptide-Specific Tolerance–Based Strategies for Restoring Self-Tolerance in CNS Autoimmune Disease. International Reviews of Immunology 24:5-6, 361-392
     

325. 325

     Roy Eldor, Irun R. Cohen, Itamar Raz. (2005) Innovative Immune-Based Therapeutic Approaches for the Treatment of Type 1 Diabetes Mellitus. International Reviews of Immunology 24:5-6, 327-339
     

326. 326

     Wei Chen, Jeffrey A. Bluestone, Kevan C. Herold. (2005) Achieving Antigen-Specific Tolerance in Diabetes: Regulating Specifically. International Reviews of Immunology 24:5-6, 287-305
     

327. 327

     Christophe Filippi, Damien Bresson, Matthias von Herrath. (2005) Antigen-Specific Induction of Regulatory T Cells for Type 1 Diabetes Therapy. International Reviews of Immunology 24:5-6, 341-360
     

328. 328

     Sicco H. Popma, Don E. Griswold, Li Li. (2005) Anti-CD3 antibodies OKT3 and hOKT3γ1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by Anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. International Immunopharmacology 5:1, 155-162
     

329. 329

     Kevin S. Goudy, Roland Tisch. (2005) Immunotherapy for the Prevention and Treatment of Type 1 Diabetes. International Reviews of Immunology 24:5-6, 307-326
     

330. 330

     Adam M. Frank, Clyde F. Barker, James F. Markmann. (2005) Comparison of Whole Organ Pancreas and Isolated Islet Transplantation for Type 1 Diabetes. Advances in Surgery 39, 137-163
     

331. 331

     Patrizia Luppi, Massimo Trucco. Autoimmunity — Type 1 Diabetes. In: Measuring Immunity. Elsevier, 2005:494-504.
     

332. 332

     Andrew Muir, Jin-Xiong She. Prenatal and Infant Nutrition in the Pathogenesis of Type 1 Diabetes. CRC Press, 2004:307-329.
     

333. 333

     Halloran , Philip F. , . (2004) Immunosuppressive Drugs for Kidney Transplantation. New England Journal of Medicine 351:26, 2715-2729
     Full Text

334. 334

     Matthias von Herrath, Dirk Homann. (2004) Islet regeneration needed for overcoming autoimmune destruction - considerations on the pathogenesis of type 1 diabetes. Pediatric Diabetes 5:s2, 23-28
     

335. 335

     Vijayakumar Ramiya, Desmond Schatz. (2004) Islet replacement vs. regeneration: Hope or hype?. Pediatric Diabetes 5:s2, 45-56
     

336. 336

     Ronald B Moss, Thomas Moll, Mohammad El-Kalay, Connie Kohne, William Soo Hoo, Jeffrey Encinas, Dennis J Carlo. (2004) Th1/Th2 cells in inflammatory disease states: therapeutic implications. Expert Opinion on Biological Therapy 4:12, 1887-1896
     

337. 337

     Andrew P Cope, Marc Feldmann. (2004) Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Current Opinion in Immunology 16:6, 780-786
     

338. 338

     Norman Ende, Ruifeng Chen, Alluru S. Reddi. (2004) Effect of human umbilical cord blood cells on glycemia and insulitis in type 1 diabetic mice. Biochemical and Biophysical Research Communications 325:3, 665-669
     

339. 339

     BRYGIDA C. BISIKIRSKA, KEVAN C. HEROLD. (2004) Use of Anti-CD3 Monoclonal Antibody to Induce Immune Regulation in Type 1 Diabetes. Annals of the New York Academy of Sciences 1037:1, 1-9
     

340. 340

     Bart O. Roep, Mark Atkinson, Matthias von Herrath. (2004) Opinion: Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nature Reviews Immunology 4:12, 989-997
     

341. 341

     Astrid G.S. van Halteren, Odette M. Tysma, Evelyne van Etten, Chantal Mathieu, Bart O. Roep. (2004) 1α,25-Dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. Journal of Autoimmunity 23:3, 233-239
     

342. 342

     E. Jaeckel, T. Becker, M. P. Manns. (2004) Organtransplantation in der Endokrinologie. Der Internist 45:11, 1268-1280
     

343. 343

     Amy E. Juedes, Matthias G. von Herrath. (2004) Regulatory T-cells in type 1 diabetes. Diabetes/Metabolism Research and Reviews 20:6, 446-451
     

344. 344

     Anita Azam, George S Eisenbarth. (2004) Immunopathogenesis and immunotherapeutic approaches to type 1A diabetes. Expert Opinion on Biological Therapy 4:10, 1569-1575
     

345. 345

     Fernando Alvarez. (2004) Treatment of autoimmune hepatitis: Current and future therapies. Current Treatment Options in Gastroenterology 7:5, 413-420
     

346. 346

     Kristina I. Rother, David M. Harlan. (2004) Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. Journal of Clinical Investigation 114:7, 877-883
     

347. 347

     Kristina I. Rother, David M. Harlan. (2004) Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. Journal of Clinical Investigation 114:7, 877-883
     

348. 348

     Dirk Homann, Matthias von Herrath. (2004) Regulatory T cells and type 1 diabetes. Clinical Immunology 112:3, 202-209
     

349. 349

     Mariela Glandt, Kevan C. Herold. (2004) Treatment of type 1 diabetes with anti-T-cell agents: From T-cell depletion to T-cell regulation. Current Diabetes Reports 4:4, 291-297
     

350. 350

     Mehboob A Hussain, Neil D Theise. (2004) Stem-cell therapy for diabetes mellitus. The Lancet 364:9429, 203-205
     

351. 351

     Steven E Kahn. (2004) Engineering a new β-cell: a critical venture requiring special attention to constantly changing physiological needs. Seminars in Cell & Developmental Biology 15:3, 359-370
     

352. 352

     Eisenbarth , George S. , Gottlieb , Peter A. , . (2004) Autoimmune Polyendocrine Syndromes. New England Journal of Medicine 350:20, 2068-2079
     Full Text

353. 353

     Camillo Ricordi, Terry B. Strom. (2004) Clinical islet transplantation: advances and immunological challenges. Nature Reviews Immunology 4:4, 259-268
     

354. 354

     Alexander C Wiseman, Ronald G Gill. (2004) Current status of clinical islet transplantation: advances and obstacles. Current Opinion in Endocrinology & Diabetes 11:2, 98-103
     

355. 355

     Constadina Panagiotopoulos, Jacqueline D. Trudeau, Rusung Tan. (2004) T-cell epitopes in type 1 diabetes. Current Diabetes Reports 4:2, 87-94
     

356. 356

     Bernhard J. Hering, Raja Kandaswamy, James V. Harmon, Jeffrey D. Ansite, Sue M. Clemmings, Tetsuya Sakai, Stephen Paraskevas, Peter M. Eckman, Junichiro Sageshima, Masahiko Nakano, Toshiya Sawada, Ippei Matsumoto, Hui J. Zhang, David E. R. Sutherland, Jeffrey A. Bluestone. (2004) Transplantation of Cultured Islets from Two-Layer Preserved Pancreases in Type 1 Diabetes with Anti-CD3 Antibody. American Journal of Transplantation 4:3, 390-401
     

357. 357

     Mark A. Sperling. (2004) The expanding horizons of Pediatric Diabetes. Pediatric Diabetes 5:1, 1-2
     

358. 358

     Roberto Mallone, Gerald T Nepom. (2004) MHC Class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clinical Immunology 110:3, 232-242
     

359. 359

     Kevan C. Herold. (2004) Treatment of type 1 diabetes mellitus to preserve insulin secretion. Endocrinology and Metabolism Clinics of North America 33:1, 93-111
     

360. 360

     Urs Christen, Amy Juedes, Dirk Homann, Matthias G. von Herrath. (2004) Virally induced inflammation and therapeutic avenues in type 1 diabetes. Endocrinology and Metabolism Clinics of North America 33:1, 45-58
     

361. 361

     James A. Ruggles, Donald Kelemen, Alain Baron. (2004) Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration. Endocrinology and Metabolism Clinics of North America 33:1, 239-252
     

362. 362

     Peter G. Stock, Jeffrey A. Bluestone. (2004) Beta-Cell Replacement for Type I Diabetes. Annual Review of Medicine 55:1, 133-156
     

363. 363

     Sefina Arif, Timothy I. Tree, Thomas P. Astill, Jennifer M. Tremble, Amanda J. Bishop, Colin M. Dayan, Bart O. Roep, Mark Peakman. (2004) Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. Journal of Clinical Investigation 113:3, 451-463
     

364. 364

     Sefina Arif, Timothy I. Tree, Thomas P. Astill, Jennifer M. Tremble, Amanda J. Bishop, Colin M. Dayan, Bart O. Roep, Mark Peakman. (2004) Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. Journal of Clinical Investigation 113:3, 451-463
     

365. 365

     Sulaiman A Nanji, A M James Shapiro. (2004) Islet Transplantation in Patients with Diabetes Mellitus. BioDrugs 18:5, 315-328
     

366. 366

     A. M. James Shapiro, Sulaiman A. Nanji, Jonathan R. T. Lakey. (2003) Clinical islet transplant: current and future directions towards tolerance. Immunological Reviews 196:1, 219-236
     

367. 367

     Herve Bachelez. (2003) Immunotherapy of skin diseases by targeting T cells. Experimental Dermatology 12:6, 921-923
     

368. 368

     Johanna Paronen, George S. Eisenbarth. Immunopathogenesis of Type 1 Diabetes in Western Society. In: International Textbook of Diabetes Mellitus. John Wiley & Sons, Ltd, 2003.
     

369. 369

     M. KOULMANDA, A. QIPO, H. AUCHINCLOSS, R. N. SMITH. (2003) Effects of streptozotocin on autoimmune diabetes in NOD mice. Clinical and Experimental Immunology 134:2, 210-216
     

370. 370

     THOMAS MANDRUP-POULSEN. (2003) Beta Cell Death and Protection. Annals of the New York Academy of Sciences 1005:1, 32-42
     

371. 371

     Edmond A. Ryan, Jonathan R.T. Lakey, Breay W. Paty, A.M. James Shapiro. Islet Transplantation. In: International Textbook of Diabetes Mellitus. John Wiley & Sons, Ltd, 2003.
     

372. 372

     Jonathan Shaw, Gary Dowse, Paul Zimmet, K.G.M.M. Alberti. Screening for Diabetes and Glucose Intolerance. In: International Textbook of Diabetes Mellitus. John Wiley & Sons, Ltd, 2003.
     

373. 373

     Darcy S. Majka, V. Michael Holers. (2003) Can we accurately predict the development of rheumatoid arthritis in the preclinical phase?. Arthritis & Rheumatism 48:10, 2701-2705
     

374. 374

     L. RENDERS, T. VALERIUS. (2003) Engineered CD3 antibodies for immunosuppression. Clinical and Experimental Immunology 133:3, 307-309
     

375. 375

     JEAN-FRANÇOIS BACH. (2003) Autoimmune Diseases as the Loss of Active “Self-Control”. Annals of the New York Academy of Sciences 998:1, 161-177
     

376. 376

     R. T. MEIJER, S. SURACHNO, S. L. YONG, F. J. BEMELMAN, S. FLORQUIN, I. J. M. TEN BERGE, P. T. A. SCHELLEKENS. (2003) Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody. Clinical and Experimental Immunology 133:3, 485-492
     

377. 377

     Maria-Grazia Roncarolo, Manuela Battaglia, Silvia Gregori. (2003) The role of interleukin 10 in the control of autoimmunity. Journal of Autoimmunity 20:4, 269-272
     

378. 378

     Kevan C. Herold, Joshua B. Burton, Fleur Francois, Ena Poumian-Ruiz, Mariela Glandt, Jeffrey A. Bluestone. (2003) Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). Journal of Clinical Investigation 111:3, 409-418
     

379. 379

     Kevan C. Herold, Joshua B. Burton, Fleur Francois, Ena Poumian-Ruiz, Mariela Glandt, Jeffrey A. Bluestone. (2003) Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). Journal of Clinical Investigation 111:3, 409-418
     

380. 380

     Nikolai Petrovsky, Diego Silva, Desmond A Schatz. (2003) Vaccine Therapies for the Prevention of Type 1 Diabetes Mellitus. Pediatric Drugs 5:9, 575-582
     

381. 381

     Petri Kulmala. (2003) Prediabetes in Children. Pediatric Drugs 5:4, 211-221
     

382. 382

     Teresa Español. (2003) Tratamiento con anticuerpos monoclonales. Medicina Clínica 121:2, 61-62
     

383. 383

     Eva Aguilera, Mónica Recasens, Rosa A. Morínigo, Roser Casamitjana, Josep Oriola, Guadalupe Ercilla, Ignacio Conget. (2003) Características clínicas, metabólicas, inmunológicas y genotípicas de un grupo de adolescentes y adultos con diabetes mellitus tipo 1A. Inicio y pronóstico a corto plazo. Medicina Clínica 120:4, 121-124
     

384. 384

     Rita Bottino, A. N. Balamurugan, Nick Giannoukakis, Massimo Trucco. (2002) Islet/pancreas transplantation: challenges for pediatrics. Pediatric Diabetes 3:4, 210-223
     

385. 385

     Gerald T Nepom. (2002) Therapy of autoimmune diseases: clinical trials and new biologics. Current Opinion in Immunology 14:6, 812-815
     

386. 386

     Dwaine F Emerich. (2002) Islet transplantation for diabetes: current status and future prospects. Expert Opinion on Biological Therapy 2:8, 793-803
     

387. 387

     Adrian Bot, William J Phillips, Matthias von Herrath. (2002) Antigen-based immune modulation: DNA vectors and beyond. Expert Opinion on Biological Therapy 2:8, 929-942
     

388. 388

     Maria A Curotto de Lafaille, Juan J Lafaille. (2002) CD4+ regulatory T cells in autoimmunity and allergy. Current Opinion in Immunology 14:6, 771-778
     

389. 389

     (2002) Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus. New England Journal of Medicine 347:14, 1116-1117
     Free Full Text

390. 390

     Emma L Masteller, Jeffrey A Bluestone. (2002) Immunotherapy of insulin-dependent diabetes mellitus. Current Opinion in Immunology 14:5, 652-659
     

391. 391

     Erika Check. (2002) Immunology: The virtue of tolerance. Nature 418:6896, 364-366
     

392. 392

     Paolo Pozzilli. (2002) The DPT-1 trial: a negative result with lessons for future type 1 diabetes prevention. Diabetes/Metabolism Research and Reviews 18:4, 257-259
     

393. 393

     &NA;. (2002) OKT3-??1-ala-ala beneficial in new-onset type 1 diabetes. Inpharma Weekly &NA;:1341, 11
     

394. 394

     Gale , Edwin A.M. , . (2002) Can We Change the Course of Beta-Cell Destruction in Type 1 Diabetes?. New England Journal of Medicine 346:22, 1740-1742
     Full Text

Letters